Chemical: Drug
warfarin

Available Prescribing Info

Dosing Guidelines
  1. CPIC Guideline for warfarin and CYP2C9,VKORC1
last updated 06/19/2014

1. CPIC Guideline for warfarin and CYP2C9,VKORC1

Summary

The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on http://www.warfarindosing.org 

Annotation

November 2013 Update

CPIC guideline authors are aware of several recently published studies on warfarin pharmacogenetics [Articles:24251361, 24251363, 24251360]. These papers have prompted several opinion pieces [Articles:24328463, 24251364]. The authors are evaluating the information, which will be incorporated into the next update of the CPIC guideline on warfarin.

October 2011

Advance online publication September 2011.

  • Guideline regarding the use of pharmacogenomic tests in dosing for warfarin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC).
  • These guidelines are applicable to:
    • adult patients
  • Excerpt from the 2011 warfarin dosing guideline:
    • "Pharmacogenetic algorithm-based warfarin dosing: Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [Articles:18305455, 19228618, 18574025]. Two algorithms perform well in estimating stable warfarin dose across different ethnic populations; [Articles:18305455, 19228618] these were created using more than 5,000 subjects. Dosing algorithms using genetics outperform nongenetic clinical algorithms and fixed-dose approaches in dose prediction [Articles:18305455, 19228618]. The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on http://www.warfarindosing.org (offering both high-performing algorithms [Articles:18305455, 19228618]). The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium is also online, at IWPC Pharmacogenetic Dosing Algorithm. The two algorithms provide very similar dose recommendations."
    • "Approach to pharmacogenetic-based warfarin dosing without access to dosing algorithms: In 2007, the FDA modified the warfarin label, stating that CYP2C9 and VKORC1 genotypes may be useful in determining the optimal initial dose of warfarin [Article:17906972]. The label was further updated in 2010 to include a table (Table 1) describing recommendations for initial dosing ranges for patients with different combinations of CYP2C9 and VKORC1 genotypes. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [Article:21272753]. Therefore, the use of pharmacogenetic algorithm-based dosing is recommended when possible, although if electronic means for such dosing are not available, the table-based dosing approaches (Table 1) are suggested. The range of doses by VKORC1 genotype and the range of dose recommendations/predictions by the FDA table and algorithm are shown in Figure 2."
  • Download and read:

Figure 2. Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by VKORC1 -1639G>A genotype.

Adapted from Figure 2 of the 2011 guideline manuscript

CPIC warfarin dosing guideline

Figure 2 Legend: Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by VKORC1 -1639G>A genotype in 3,616 patients recruited by the International Warfarin Pharmacogenetics Consortium (IWPC) who did not carry the CYP2C9*2 or *3 allele (i.e., coded as *1/*1 for US Food and Drug Administration (FDA) table and algorithm dosing). The range of doses within each genotype group recommended on the FDA table is shown via the shaded rectangle. The range of doses predicted using the IWPC dosing algorithm in these 3,616 patients is shown by the solid lines.

Figure 2 demonstrates that the range of individuals covered by the FDA table is much narrower than that of the algorithm. The article and supplement detail important variables that are not covered by the table that should also be taken into consideration.

Adapted from Table 1 of the 2011 guideline manuscript

VKORC1 Genotype (-1639G>A, rs9923231)CYP2C9*1/*1CYP2C9*1/*2CYP2C9*1/*3CYP2C9*2/*2CYP2C9*2/*3CYP2C9*3/*3
GG5-75-73-43-43-40.5-2
GA5-73-43-43-40.5-20.5-2
AA3-43-40.5-20.5-20.5-20.5-2

Reproduced from updated warfarin (Coumadin) product label.

Supplemental Table S1. Genotypes that constitute the * alleles for CYP2C9

Adapted from Table S1 of the 2011 guideline supplement

AlleleConstituted by genotypes at:Amino acid changesEnzymatic Activity
*1reference allele at all positionsNormal
*2C>T at rs1799853R144CDecreased
*3A>C at rs1057910I359LDecreased


Annotated Labels

  1. FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1
  2. HCSC Label for warfarin and CYP2C9,VKORC1

last updated 07/14/2014

1. FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1

Actionable PGx

Summary

Warfarin (Coumadin) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.

Annotation

The VKORC1:G-1639A polymorphism is associated with lower dose requirements for warfarin in Caucasian and Asian patients. Increased bleeding risk and lower initial warfarin dose requirements have been associated with the CYP2C9*2 and CYP2C9*3 alleles. Approximately 30% of the variance in warfarin dose could be attributed to genetic variation in VKORC1, and about 40% of dose variance could be explained taking into consideration both VKORC1 and CYP2C9 genetic polymorphisms. Accounting for genetic variation in both VKORC1 and CYP2C9, age, height, body weight, interacting drugs, and indication for warfarin therapy explained about 55% of the variability in warfarin dose. The drug label also notes that hereditary or acquired deficiency of protein C (encoded by the PROC gene) or protein S (PROS1) have been associated with tissue necrosis following administration of warfarin.

Excerpts from the warfarin drug label:

The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.

Known or suspected deficiency in protein C mediated anticoagulant response: Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the warfarin drug label. Pharmacogenomics-related dosing information is found in Table 5 on page 27.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Arteriosclerosis
    • Warnings section
    • source: PHONT
  • Atrial Fibrillation
    • Indications & usage section
    • source: PHONT
  • Cardiomyopathy, Hypertrophic
    • Precautions section
    • source: PHONT
  • Chondrodysplasia Punctata
    • Contraindications section
    • source: PHONT
  • Death
    • Contraindications section, Warnings section
    • source: PHONT
  • Death, Sudden, Cardiac
    • Indications & usage section, Warnings section
    • source: PHONT
  • Heart Diseases
    • Contraindications section, Precautions section
    • source: PHONT
  • Hemorrhage
    • Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Myocardial Infarction
    • Indications & usage section
    • source: PHONT
  • Neoplasms
    • Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Peripheral Vascular Diseases
    • Warnings section
    • source: PHONT
  • Pulmonary Embolism
    • Indications & usage section
    • source: PHONT
  • Stroke
    • Indications & usage section
    • source: PHONT
  • Thromboembolism
    • Contraindications section, Warnings section
    • source: PHONT
  • Thrombosis
    • Indications & usage section, Warnings section, Precautions section
    • source: PHONT
  • Venous Thrombosis
    • Warnings section
    • source: PHONT
  • Ventricular Fibrillation
    • Indications & usage section
    • source: PHONT
  • CYP2C9
    • dosage, metabolism/PK, Dosage & administration section, Clinical pharmacology section, Precautions section
    • source: U.S. Food and Drug Administration
  • VKORC1
    • dosage, efficacy, Dosage & administration section, Clinical pharmacology section, Precautions section
    • source: U.S. Food and Drug Administration

2. HCSC Label for warfarin and CYP2C9,VKORC1

Actionable PGx

Summary

The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the VKORC1 gene, such as -1639G>A, are also associated with changes in the dose requirement of warfarin.

Annotation

Warfarin (COUMADIN) is an anticoagulant. Excerpts from the warfarin (COUMADIN) product monograph:

A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian)...suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.

In an observational study...in 219 Swedish patients...The relative risk of over anticoagulation as measured by INR >3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.

Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G>A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined. About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs and indication for warfarin therapy in Caucasian patients. Similar observations have been reported in Asian patients.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the warfarin product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Clinical Annotation for rs2108622 (CYP4F2), warfarin, Heart Diseases, Hemorrhage, Intracranial Hemorrhages, Myocardial Infarction, Peripheral Vascular Diseases, Thromboembolism and venous thromboembolism (level 1B Dosage)

Level of Evidence
Level 1B
Type
Dosage
Variant
rs2108622
Genes
CYP4F2
Phenotypes
Heart Diseases, Hemorrhage, Intracranial Hemorrhages, Myocardial Infarction, Peripheral Vascular Diseases, Thromboembolism, venous thromboembolism
OMB Race
Mixed Population
Race Notes
Studies include White, Black or African American, Asian, Hispanic or Latino and Mixed populations.

To see the rest of this clinical annotation please register or sign in.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for warfarin

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA APOE E2 N/A N/A N/A
No VIP available CA VA APOE E3 N/A N/A N/A
No VIP available CA VA APOE E4 N/A N/A N/A
No VIP available CA VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1A N/A N/A N/A
No VIP available CA VA CYP2C19 *2 N/A N/A N/A
VIP No VIP available VA CYP2C19 *2A N/A N/A N/A
No VIP available CA VA CYP2C19 *3 N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *3A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available CA VA CYP2C9 *1 N/A N/A N/A
VIP CA VA CYP2C9 *2 N/A N/A N/A
VIP CA VA CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *4 N/A N/A N/A
No VIP available CA VA CYP2C9 *5 N/A N/A N/A
No VIP available CA VA CYP2C9 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *8 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *10 N/A N/A N/A
No VIP available CA VA CYP2C9 *11 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *12 N/A N/A N/A
No VIP available CA VA CYP2C9 *13 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *14 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *25 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *57 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *58 N/A N/A N/A
No VIP available CA VA CYP2C9 *59 N/A N/A N/A
No VIP available No VIP available VA CYP4F2 *1 N/A N/A N/A
No VIP available No VIP available VA CYP4F2 *3 N/A N/A N/A
VIP No VIP available VA VKORC1 *1 N/A N/A N/A
VIP No VIP available VA VKORC1 *2 N/A N/A N/A
VIP No VIP available VA VKORC1 *3 N/A N/A N/A
VIP No VIP available VA VKORC1 *4 N/A N/A N/A
No VIP available No VIP available VA VKORC1 H1 N/A N/A N/A
No VIP available No VIP available VA VKORC1 H2 N/A N/A N/A
No VIP available No VIP available VA VKORC1 H7 N/A N/A N/A
No VIP available No VIP available VA VKORC1 H8 N/A N/A N/A
No VIP available No VIP available VA VKORC1 H9 N/A N/A N/A
rs10090884 NC_000008.10:g.11599570A>C, NC_000008.11:g.11742061A>C, NG_008177.2:g.70143A>C, NM_001308093.1:c.617-6855A>C, NM_001308094.1:c.-5-6855A>C, NM_002052.4:c.617-6858A>C, XM_005272384.1:c.617-6855A>C, XM_005272385.1:c.617-6855A>C, XM_005272385.3:c.617-6855A>C, XM_005272386.1:c.617-6855A>C, XM_005272387.1:c.-5-6855A>C, XM_006716248.1:c.617-6855A>C, XM_006716249.2:c.-5-6855A>C, XM_011543817.1:c.617-6855A>C, XM_011543818.1:c.617-6855A>C, rs60444879
A > C
SNP
rs10239977
C > T
SNP
rs1042580 NC_000020.10:g.23027621T>C, NC_000020.11:g.23046984T>C, NG_012027.1:g.7681A>G, NM_000361.2:c.*793A>G, rs3167753
T > C
SNP
rs1043550 NC_000007.13:g.128409225A>G, NC_000007.14:g.128769171A>G, NG_033110.1:g.34880A>G, NM_001130674.2:c.*4A>G, NM_001199671.1:c.*4A>G, NM_001199672.1:c.*4A>G, NM_001199673.1:c.*77A>G, NM_001219.4:c.*4A>G, NR_074086.1:n.678A>G, XM_011516588.1:c.*4A>G, rs11545537, rs17475700, rs3183116, rs61381822
A > -
A > G
SNP
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
rs1048943 NC_000015.10:g.74720644T>C, NC_000015.9:g.75012985T>C, NG_008431.1:g.3103T>C, NM_000499.3:c.1384A>G, NM_000499.4:c.1384A>G, NM_001319216.1:c.1297A>G, NM_001319217.1:c.1384A>G, NP_000490.1:p.Ile462Val, NP_001306145.1:p.Ile433Val, NP_001306146.1:p.Ile462Val, XM_005254185.1:c.1384A>G, XM_005254186.1:c.1384A>G, XM_005254187.1:c.1300A>G, XM_005254188.1:c.1297A>G, XM_005254189.1:c.601A>G, XP_005254242.1:p.Ile462Val, XP_005254243.1:p.Ile462Val, XP_005254244.1:p.Ile434Val, XP_005254245.1:p.Ile433Val, XP_005254246.1:p.Ile201Val, rs17861092, rs3188998, rs386513458, rs52810784
T > C
SNP
I462V
rs104894539 NC_000016.10:g.31094645C>A, NC_000016.9:g.31105966C>A, NG_011564.1:g.5311G>T, NM_001311311.1:c.85G>T, NM_024006.4:c.85G>T, NM_024006.5:c.85G>T, NM_206824.2:c.85G>T, NP_001298240.1:p.Val29Leu, NP_076869.1:p.Val29Leu, NP_996560.1:p.Val29Leu, XM_005255568.1:c.85G>T, XM_011545943.1:c.85G>T, XM_011545944.1:c.85G>T, XM_011545945.1:c.85G>T, XP_005255625.1:p.Val29Leu, XP_011544245.1:p.Val29Leu, XP_011544246.1:p.Val29Leu, XP_011544247.1:p.Val29Leu, XR_243303.1:n.734G>T, XR_950848.1:n.873G>T
C > A
SNP
V29L
rs104894540 NC_000016.10:g.31094596A>G, NC_000016.9:g.31105917A>G, NG_011564.1:g.5360T>C, NM_001311311.1:c.134T>C, NM_024006.4:c.134T>C, NM_024006.5:c.134T>C, NM_206824.2:c.134T>C, NP_001298240.1:p.Val45Ala, NP_076869.1:p.Val45Ala, NP_996560.1:p.Val45Ala, XM_005255568.1:c.134T>C, XM_011545943.1:c.134T>C, XM_011545944.1:c.134T>C, XM_011545945.1:c.134T>C, XP_005255625.1:p.Val45Ala, XP_011544245.1:p.Val45Ala, XP_011544246.1:p.Val45Ala, XP_011544247.1:p.Val45Ala, XR_243303.1:n.783T>C, XR_950848.1:n.922T>C, rs28940303
A > G
SNP
V45A
rs104894541 NC_000016.10:g.31094558T>C, NC_000016.9:g.31105879T>C, NG_011564.1:g.5398A>G, NM_001311311.1:c.172A>G, NM_024006.4:c.172A>G, NM_024006.5:c.172A>G, NM_206824.2:c.172A>G, NP_001298240.1:p.Arg58Gly, NP_076869.1:p.Arg58Gly, NP_996560.1:p.Arg58Gly, XM_005255568.1:c.172A>G, XM_011545943.1:c.172A>G, XM_011545944.1:c.172A>G, XM_011545945.1:c.172A>G, XP_005255625.1:p.Arg58Gly, XP_011544245.1:p.Arg58Gly, XP_011544246.1:p.Arg58Gly, XP_011544247.1:p.Arg58Gly, XR_243303.1:n.821A>G, XR_950848.1:n.960A>G, rs28940304
T > C
SNP
R58G
rs104894542 NC_000016.10:g.31091243A>C, NC_000016.9:g.31102564A>C, NG_011564.1:g.8713T>G, NM_001311311.1:c.467T>G, NM_024006.4:c.383T>G, NM_024006.5:c.383T>G, NM_206824.2:c.273T>G, NP_001298240.1:p.Leu156Arg, NP_076869.1:p.Leu128Arg, NP_996560.1:p.Ala91=, XM_005255568.1:c.467T>G, XM_011545816.1:c.-2434T>G, XM_011545817.1:c.-2434T>G, XM_011545818.1:c.-2434T>G, XM_011545819.1:c.-2434T>G, XM_011545820.1:c.-2434T>G, XM_011545943.1:c.467T>G, XM_011545944.1:c.383T>G, XM_011545945.1:c.273T>G, XP_005255625.1:p.Leu156Arg, XP_011544245.1:p.Leu156Arg, XP_011544246.1:p.Leu128Arg, XP_011544247.1:p.Ala91=, XR_243303.1:n.932T>G, XR_950848.1:n.1171T>G, rs28940305
A > C
SNP
L156A/R
rs10509680 NC_000010.10:g.96734339G>T, NC_000010.11:g.94974582G>T, NG_008385.1:g.40925G>T, NM_000771.3:c.961+2337G>T, XM_005269575.1:c.961+2337G>T, rs45630770, rs45631363
G > T
SNP
rs10517 NC_000016.10:g.69709857A>G, NC_000016.9:g.69743760A>G, NG_011504.1:g.21774T>C, NM_000903.2:c.*1119T>C, NM_001025433.1:c.*1119T>C, NM_001025434.1:c.*1119T>C, NM_001286137.1:c.*1119T>C, XM_005255830.1:c.*1119T>C, rs1131357, rs3191227, rs386514164, rs60683463
A > G
SNP
rs1051740 NC_000001.10:g.226019633T>C, NC_000001.11:g.225831932T>C, NG_009776.1:g.26837T>C, NM_000120.3:c.337T>C, NM_001136018.3:c.337T>C, NM_001291163.1:c.337T>C, NP_000111.1:p.Tyr113His, NP_001129490.1:p.Tyr113His, NP_001278092.1:p.Tyr113His, XM_005273085.1:c.337T>C, XP_005273142.1:p.Tyr113His, rs16845366, rs17417482, rs1800444, rs2259405, rs3192120, rs52794507, rs59266540
T > C
SNP
Y113H
rs1051741 NC_000001.10:g.226032229C>T, NC_000001.11:g.225844528C>T, NG_009776.1:g.39433C>T, NM_000120.3:c.1071C>T, NM_001136018.3:c.1071C>T, NM_001291163.1:c.1071C>T, NP_000111.1:p.Asn357=, NP_001129490.1:p.Asn357=, NP_001278092.1:p.Asn357=, XM_005273085.1:c.1071C>T, XP_005273142.1:p.Asn357=, XR_949163.1:n.2830+2310G>A, rs2292569, rs3192122, rs56555531, rs60193447
C > T
SNP
N357N
rs1057868 NC_000007.13:g.75615006C>T, NC_000007.14:g.75985688C>T, NG_008930.1:g.75587C>T, NM_000941.2:c.1508C>T, NP_000932.3:p.Ala503Val, NW_003871064.1:g.3514924C>T, XM_005250459.1:c.1508C>T, XM_005250460.1:c.1205C>T, XM_005250461.1:c.932C>T, XM_005277600.1:c.1508C>T, XM_005277601.1:c.1205C>T, XM_005277602.1:c.932C>T, XP_005250516.1:p.Ala503Val, XP_005250517.1:p.Ala402Val, XP_005250518.1:p.Ala311Val, XP_005277657.1:p.Ala503Val, XP_005277658.1:p.Ala402Val, XP_005277659.1:p.Ala311Val, rs17840495, rs17846082, rs17859083, rs3198400, rs57699079
C > T
SNP
A503V
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
rs10654848 unknown
rs10871454 NC_000016.10:g.31036758C>T, NC_000016.9:g.31048079C>T, NM_001272095.1:c.145-1168C>T, NM_001272096.1:c.373-1168C>T, NM_004604.4:c.379-1168C>T, XM_005255521.1:c.367-1168C>T, XM_011545925.1:c.-52+997C>T, rs58361488
C > T
SNP
rs11150606 NC_000016.10:g.31087690T>C, NC_000016.9:g.31099011T>C, NM_001039503.2:c.89A>G, NP_001034592.1:p.Gln30Arg, XM_005255293.1:c.89A>G, XM_005255294.1:c.-530A>G, XM_011545816.1:c.89A>G, XM_011545817.1:c.89A>G, XM_011545818.1:c.89A>G, XM_011545819.1:c.89A>G, XM_011545820.1:c.89A>G, XP_005255350.1:p.Gln30Arg, XP_011544118.1:p.Gln30Arg, XP_011544119.1:p.Gln30Arg, XP_011544120.1:p.Gln30Arg, XP_011544121.1:p.Gln30Arg, XP_011544122.1:p.Gln30Arg
T > C
SNP
Q30R
rs112936952
- > TTG
- > TTGTTG
- > TTGTTGTTG
- > TTGTTGTTGTTG
microsatellite
rs1131873 NC_000001.10:g.226019653G>A, NC_000001.11:g.225831952G>A, NG_009776.1:g.26857G>A, NM_000120.3:c.357G>A, NM_001136018.3:c.357G>A, NM_001291163.1:c.357G>A, NP_000111.1:p.Lys119=, NP_001129490.1:p.Lys119=, NP_001278092.1:p.Lys119=, XM_005273085.1:c.357G>A, XP_005273142.1:p.Lys119=, rs11540968, rs17417489, rs2292566, rs3192121, rs386563972, rs59577327
G > A
SNP
K119K
rs11636419 NC_000015.10:g.74755259A>G, NC_000015.9:g.75047600A>G, NG_008431.1:g.37718A>G, NM_000761.3:c.*171A>G, NM_000761.4:c.*171A>G, rs28969407
A > G
SNP
rs11653 NC_000007.13:g.128409580T>A, NC_000007.14:g.128769526T>A, NG_033110.1:g.35235T>A, NM_001130674.2:c.*359T>A, NM_001199671.1:c.*359T>A, NM_001199672.1:c.*359T>A, NM_001199673.1:c.*432T>A, NM_001219.4:c.*359T>A, NR_074086.1:n.1033T>A, XM_011516588.1:c.*359T>A, rs1043570, rs11545533, rs17475721, rs3183137, rs3807311
T > -
T > A
SNP
rs11676382 NC_000002.11:g.85777633C>G, NC_000002.12:g.85550510C>G, NG_011811.2:g.16025G>C, NM_000821.6:c.2084+45G>C, NM_001142269.3:c.1913+45G>C, XM_005264259.1:c.2078+45G>C, XM_005264259.3:c.2078+45G>C, XM_011532764.1:c.1262+45G>C, XM_011532765.1:c.1262+45G>C, XR_939677.1:n.2216G>C
C > G
SNP
rs1205 NC_000001.10:g.159682233C>T, NC_000001.11:g.159712443C>T, NG_013007.1:g.7147G>A, NM_000567.2:c.*1082G>A, XM_005244904.1:c.*374G>A, XM_011509207.1:c.*374G>A, rs16955, rs17860476, rs3190272
C > T
SNP
rs12065184 NC_000001.10:g.161278677A>C, NC_000001.11:g.161308887A>C, NG_008055.1:g.6086T>G, NM_000530.6:c.67+952T>G, NM_000530.7:c.67+952T>G, NM_001315491.1:c.67+952T>G, rs52829536, rs59221238
A > C
SNP
rs12248560 NC_000010.10:g.96521657C>T, NC_000010.11:g.94761900C>T, NG_008384.2:g.4195C>T, NM_000769.2:c.-806C>T, rs117093607, rs17442305, rs17879736
C > A
C > T
SNP
rs12460590 NC_000019.10:g.40875742A>C, NC_000019.9:g.41381647A>C, NG_007960.1:g.12011T>G, NM_000764.2:c.1436T>G, NM_030589.2:c.1283T>G, NP_000755.2:p.Val479Gly, NP_085079.2:p.Val428Gly, XR_935754.1:n.1975T>G, rs75344699
A > C
SNP
V479G
rs12714145 NC_000002.11:g.85787341C>T, NC_000002.12:g.85560218C>T, NG_011811.2:g.6317G>A, NM_000821.6:c.214+597G>A, NM_001142269.3:c.44-1143G>A, NM_001311312.1:c.214+597G>A, XM_005264259.1:c.214+597G>A, XM_005264259.3:c.214+597G>A, XM_011532764.1:c.-445+597G>A, XM_011532765.1:c.-444-1143G>A, XR_939677.1:n.279+597G>A, rs59983638
C > T
SNP
rs12777823 NC_000010.10:g.96405502G>A, NC_000010.11:g.94645745G>A, rs56463295, rs59201782
G > A
SNP
rs12782374 NC_000010.10:g.96695351G>A, NC_000010.11:g.94935594G>A, NG_008385.1:g.1937G>A
G > A
SNP
rs1415774 NC_000020.10:g.33765616A>G, NC_000020.11:g.35177813A>G, NG_032899.1:g.10843A>G, NM_006404.4:c.*1000A>G, XM_005260251.1:c.601+1367A>G, XM_011528496.1:c.601+1367A>G, rs17321460, rs58892463, rs60278957
A > G
SNP
rs1687390 NC_000009.11:g.117089888G>A, NC_000009.12:g.114327608G>A, NG_012108.1:g.9586G>A
G > A
SNP
rs17126068
A > G
SNP
rs17650 NC_000009.11:g.117085526G>A, NC_000009.12:g.114323246G>A, NG_012108.1:g.5224G>A, NM_000607.2:c.113G>A, NP_000598.2:p.Arg38Gln, rs1071593, rs147960186, rs3181587, rs71503597
G > A
SNP
R38Q
rs17708472 NC_000016.10:g.31094032G>A, NC_000016.9:g.31105353G>A, NG_011564.1:g.5924C>T, NM_001311311.1:c.173+525C>T, NM_024006.5:c.173+525C>T, NM_206824.2:c.173+525C>T, XM_005255568.1:c.173+525C>T, XM_011545943.1:c.173+525C>T, XM_011545944.1:c.173+525C>T, XM_011545945.1:c.173+525C>T, XR_243303.1:n.822+525C>T, XR_950848.1:n.961+525C>T, rs386544324
G > A
SNP
rs17878544 NC_000016.10:g.31096606T>C, NC_000016.9:g.31107927T>C, NG_011564.1:g.3350A>G, NM_001311311.1:c.-1877A>G, NM_024006.5:c.-1877A>G, NM_206824.2:c.-1877A>G, XM_005255568.1:c.-1877A>G, XM_011545943.1:c.-1877A>G, XM_011545944.1:c.-1490A>G, XM_011545945.1:c.-1490A>G, XR_243303.1:n.-1228A>G, XR_950848.1:n.-269A>G
T > C
SNP
rs17880887 NC_000016.10:g.31099180G>T, NC_000016.9:g.31110501G>T, NG_011564.1:g.776C>A
G > T
SNP
rs17886199 NC_000016.10:g.31093126A>G, NC_000016.9:g.31104447A>G, NG_011564.1:g.6830T>C, NM_001311311.1:c.283+186T>C, NM_024006.5:c.283+186T>C, NM_206824.2:c.173+1431T>C, XM_005255568.1:c.283+186T>C, XM_011545943.1:c.283+186T>C, XM_011545944.1:c.283+186T>C, XM_011545945.1:c.173+1431T>C, XR_243303.1:n.832+186T>C, XR_950848.1:n.1071+186T>C
A > G
SNP
rs1799853 NC_000010.10:g.96702047C=, NC_000010.10:g.96702047C>T, NC_000010.11:g.94942290C=, NC_000010.11:g.94942290C>T, NG_008385.1:g.8633C=, NG_008385.1:g.8633C>T, NM_000771.3:c.430C=, NM_000771.3:c.430C>T, NP_000762.2:p.Arg144=, NP_000762.2:p.Arg144Cys, XM_005269575.1:c.430C=, XM_005269575.1:c.430C>T, XP_005269632.1:p.Arg144=, XP_005269632.1:p.Arg144Cys, rs17110268, rs28371674, rs33968134, rs60690363
C > T
SNP
R144C
rs1800566 NC_000016.10:g.69711242G>A, NC_000016.9:g.69745145G>A, NG_011504.1:g.20389C>T, NM_000903.2:c.559C>T, NM_001025433.1:c.457C>T, NM_001025434.1:c.445C>T, NM_001286137.1:c.343C>T, NP_000894.1:p.Pro187Ser, NP_001020604.1:p.Pro153Ser, NP_001020605.1:p.Pro149Ser, NP_001273066.1:p.Pro115Ser, XM_005255830.1:c.343C>T, XP_005255887.1:p.Pro115Ser, rs4134727, rs4149351, rs57135274
G > A
SNP
P187S
rs1877724 NC_000001.10:g.226013355C>T, NC_000001.11:g.225825654C>T, NG_009776.1:g.20559C>T, NM_000120.3:c.-6+110C>T, NM_001136018.3:c.-5-3071C>T, NM_001291163.1:c.-5-3071C>T, XM_005273085.1:c.-5-3071C>T, rs2854454, rs3738041, rs57352464
C > T
SNP
rs2069514 NC_000015.10:g.74745879G>A, NC_000015.9:g.75038220G>A, NG_008431.1:g.28338G>A
G > A
SNP
rs2069919 NC_000002.11:g.128179553G>A, NC_000002.12:g.127421977G>A, NG_016323.1:g.8558G>A, NM_000312.3:c.237+528G>A, XM_005263715.1:c.420+528G>A, XM_005263715.3:c.420+528G>A, XM_005263716.1:c.300+528G>A, XM_005263716.3:c.300+528G>A, XM_005263717.1:c.300+528G>A, XM_005263717.3:c.300+528G>A, rs57786626
G > A
SNP
rs2108622 NC_000019.10:g.15879621C>T, NC_000019.9:g.15990431C>T, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, NP_001073.3:p.Val433Met, rs116975254, rs52819608, rs57319528
C > T
SNP
V433M
rs216013 NC_000012.11:g.2729632A>G, NC_000012.12:g.2620466A>G, NG_008801.2:g.654681A>G, NM_000719.6:c.3828+8453A>G, NM_001129827.1:c.3888+8453A>G, NM_001129829.1:c.3828+8453A>G, NM_001129830.1:c.3828+8453A>G, NM_001129830.2:c.3828+8453A>G, NM_001129831.1:c.3828+8453A>G, NM_001129832.1:c.3888+8453A>G, NM_001129833.1:c.3828+8453A>G, NM_001129834.1:c.3828+8453A>G, NM_001129835.1:c.3828+8453A>G, NM_001129836.1:c.3828+8453A>G, NM_001129837.1:c.3828+8453A>G, NM_001129838.1:c.3828+8453A>G, NM_001129839.1:c.3828+8453A>G, NM_001129840.1:c.3828+8453A>G, NM_001129841.1:c.3828+8453A>G, NM_001129842.1:c.3828+8453A>G, NM_001129843.1:c.3828+8453A>G, NM_001129844.1:c.3819+8453A>G, NM_001129846.1:c.3828+8453A>G, NM_001167623.1:c.3828+8453A>G, NM_001167624.2:c.3828+8453A>G, NM_001167625.1:c.3828+8453A>G, NM_199460.3:c.3888+8453A>G, XM_005253765.1:c.4038+8453A>G, XM_005253766.1:c.3897+8453A>G, XM_005253767.1:c.3837+8453A>G, XM_005253768.1:c.3897+8453A>G, XM_005253769.1:c.3837+8453A>G, XM_005253770.1:c.3837+8453A>G, XM_005253771.1:c.3837+8453A>G, XM_005253772.1:c.3837+8453A>G, XM_005253773.1:c.3897+8453A>G, XM_005253774.1:c.3837+8453A>G, XM_005253775.1:c.3837+8453A>G, XM_005253776.1:c.3837+8453A>G, XM_005253777.1:c.3837+8453A>G, XM_005253778.1:c.3837+8453A>G, XM_005253779.1:c.3837+8453A>G, XM_005253780.1:c.3837+8453A>G, XM_005253781.1:c.3837+8453A>G, XM_005253782.1:c.3837+8453A>G, XM_005253783.1:c.3837+8453A>G, XM_005253784.1:c.3837+8453A>G, XM_005253785.1:c.3837+8453A>G, XM_005253786.1:c.3828+8453A>G, XM_005253787.1:c.3837+8453A>G, XM_005253788.1:c.1650+8453A>G, XM_006719017.1:c.3918+8453A>G, XM_011521017.1:c.2988+8453A>G, XM_011521018.1:c.2433+8453A>G, XM_011521019.1:c.543+8453A>G, XM_011521020.1:c.3993+8453A>G, XM_011521021.1:c.3828+8453A>G, XM_011521022.1:c.3828+8453A>G, XM_011521023.1:c.3903+8453A>G, rs59232965
A > G
SNP
rs2189784 NC_000019.10:g.15848390G>A, NC_000019.9:g.15959200G>A, rs60426306
G > A
SNP
rs2234922 NC_000001.10:g.226026406A>G, NC_000001.11:g.225838705A>G, NG_009776.1:g.33610A>G, NM_000120.3:c.416A>G, NM_001136018.3:c.416A>G, NM_001291163.1:c.416A>G, NP_000111.1:p.His139Arg, NP_001129490.1:p.His139Arg, NP_001278092.1:p.His139Arg, XM_005273085.1:c.416A>G, XP_005273142.1:p.His139Arg, rs59975602
A > G
SNP
H139R
rs2242480 NC_000007.13:g.99361466C>T, NC_000007.14:g.99763843C>T, NG_008421.1:g.25343G>A, NM_001202855.2:c.1023+12G>A, NM_017460.5:c.1026+12G>A, XM_011515841.1:c.1026+12G>A, XM_011515842.1:c.1023+12G>A, rs10364667, rs12721630, rs17161804, rs28969389, rs59491337, rs72494459, rs9655766
C > T
SNP
rs2260863 NC_000001.10:g.226019774G>C, NC_000001.11:g.225832073G>C, NG_009776.1:g.26978G>C, NM_000120.3:c.364+114G>C, NM_001136018.3:c.364+114G>C, NM_001291163.1:c.364+114G>C, XM_005273085.1:c.364+114G>C, rs57978216
G > C
SNP
rs2286461 NC_000004.11:g.15963673G>A, NC_000004.12:g.15962050G>A, NM_031950.3:c.*20+388C>T, rs17760443, rs386563644, rs61559848
G > A
SNP
rs2288344
T > G
SNP
rs2290228 NC_000007.13:g.128388648G>A, NC_000007.14:g.128748594G>A, NG_033110.1:g.14303G>A, NM_001130674.2:c.11G>A, NM_001199671.1:c.35G>A, NM_001199672.1:c.35G>A, NM_001199673.1:c.11G>A, NM_001219.4:c.11G>A, NP_001124146.1:p.Arg4Gln, NP_001186600.1:p.Arg12Gln, NP_001186601.1:p.Arg12Gln, NP_001186602.1:p.Arg4Gln, NP_001210.1:p.Arg4Gln, NR_074086.1:n.141+9162G>A, XM_011516588.1:c.-406G>A, rs10399443, rs11545532, rs61408000
G > A
SNP
R4Q
rs2304429
C > T
SNP
rs2359612 NC_000016.10:g.31092475A>G, NC_000016.9:g.31103796A>G, NG_011564.1:g.7481T>C, NM_001311311.1:c.367+308T>C, NM_024006.5:c.283+837T>C, NM_206824.2:c.174-1133T>C, XM_005255568.1:c.367+308T>C, XM_011545943.1:c.367+308T>C, XM_011545944.1:c.283+837T>C, XM_011545945.1:c.174-1133T>C, XR_243303.1:n.832+837T>C, XR_950848.1:n.1071+837T>C, rs17884333
A > G
SNP
rs2501873 NC_000001.10:g.161204538C>T, NC_000001.11:g.161234748C>T, NG_029113.1:g.8463G>A, NM_001077469.2:c.238+1099G>A, NM_001077470.2:c.151+1099G>A, NM_001077471.2:c.238+1099G>A, NM_001077472.2:c.151+1099G>A, NM_001077473.2:c.151+1099G>A, NM_001077474.2:c.238+1099G>A, NM_001077475.2:c.151+1099G>A, NM_001077476.2:c.151+1099G>A, NM_001077477.2:c.151+1099G>A, NM_001077478.2:c.238+1099G>A, NM_001077479.2:c.151+1099G>A, NM_001077480.2:c.238+1099G>A, NM_001077481.2:c.238+1099G>A, NM_001077482.2:c.238+1099G>A, NM_005122.4:c.238+1099G>A, XM_005245693.1:c.454+1099G>A, XM_005245693.3:c.454+1099G>A, XM_005245694.1:c.454+1099G>A, XM_005245694.3:c.454+1099G>A, XM_005245695.1:c.454+1099G>A, XM_005245696.1:c.454+1099G>A, XM_005245697.1:c.238+1099G>A, XM_005245697.3:c.238+1099G>A, XM_005245698.1:c.454+1099G>A, XM_005245699.1:c.454+1099G>A, XM_011510237.1:c.454+1099G>A, rs57345476, rs74230383
C > T
SNP
rs2592551 NC_000002.11:g.85780131G>A, NC_000002.12:g.85553008G>A, NG_011811.2:g.13527C>T, NM_000821.6:c.1218C>T, NM_001142269.3:c.1047C>T, NP_000812.2:p.Arg406=, NP_001135741.1:p.Arg349=, XM_005264259.1:c.1218C>T, XM_005264259.3:c.1218C>T, XM_011532764.1:c.396C>T, XM_011532765.1:c.396C>T, XP_005264316.1:p.Arg406=, XP_011531066.1:p.Arg132=, XP_011531067.1:p.Arg132=, XR_939677.1:n.1283C>T, rs118075290, rs61110673
G > A
SNP
R406R
rs2645400 NC_000008.10:g.11609416T>G, NC_000008.11:g.11751907T>G, NG_008177.2:g.79989T>G, NM_001308093.1:c.912+1671T>G, NM_001308094.1:c.291+1671T>G, NM_002052.4:c.909+1671T>G, XM_005272384.1:c.912+1671T>G, XM_005272385.1:c.912+1671T>G, XM_005272385.3:c.912+1671T>G, XM_005272386.1:c.912+1671T>G, XM_005272387.1:c.291+1671T>G, XM_006716248.1:c.912+1671T>G, XM_006716249.2:c.291+1671T>G, XM_011543817.1:c.912+1671T>G, XM_011543818.1:c.912+1671T>G, rs56558867, rs57596991
T > G
SNP
rs28371685 NC_000010.10:g.96740981C>T, NC_000010.11:g.94981224C>T, NG_008385.1:g.47567C>T, NM_000771.3:c.1003C>T, NP_000762.2:p.Arg335Trp, XM_005269575.1:c.1003C>T, XP_005269632.1:p.Arg335Trp, rs60219528
C > T
SNP
R335W
rs28371686 NC_000010.10:g.96741058C>G, NC_000010.11:g.94981301C>G, NG_008385.1:g.47644C>G, NM_000771.3:c.1080C>G, NP_000762.2:p.Asp360Glu, XM_005269575.1:c.1080C>G, XP_005269632.1:p.Asp360Glu, rs57527516
C > G
SNP
D360E
rs28371759 NC_000007.13:g.99361626A>G, NC_000007.14:g.99764003A>G, NG_008421.1:g.25183T>C, NM_001202855.2:c.875T>C, NM_017460.5:c.878T>C, NP_001189784.1:p.Leu292Pro, NP_059488.2:p.Leu293Pro, XM_011515841.1:c.878T>C, XM_011515842.1:c.875T>C, XP_011514143.1:p.Leu293Pro, XP_011514144.1:p.Leu292Pro, rs386574775, rs60608883
A > G
SNP
L292P
rs2860905 NC_000010.10:g.96702295G>A, NC_000010.11:g.94942538G>A, NG_008385.1:g.8881G>A, NM_000771.3:c.481+197G>A, XM_005269575.1:c.481+197G>A, rs56268370
G > A
SNP
rs2868177 NC_000007.13:g.75589903A>G, NC_000007.14:g.75960585A>G, NG_008930.1:g.50484A>G, NM_000941.2:c.188+6405A>G, NW_003871064.1:g.3489821A>G, XM_005250459.1:c.188+6405A>G, XM_005250461.1:c.-264+6405A>G, XM_005277600.1:c.188+6405A>G, XM_005277602.1:c.-264+6405A>G, rs10375158, rs59093849, rs61116122
A > G
SNP
rs2884737 NC_000016.10:g.31094233A>C, NC_000016.9:g.31105554A>C, NG_011564.1:g.5723T>G, NM_001311311.1:c.173+324T>G, NM_024006.5:c.173+324T>G, NM_206824.2:c.173+324T>G, XM_005255568.1:c.173+324T>G, XM_011545943.1:c.173+324T>G, XM_011545944.1:c.173+324T>G, XM_011545945.1:c.173+324T>G, XR_243303.1:n.822+324T>G, XR_950848.1:n.961+324T>G, rs17882154
A > C
SNP
rs2901783 NC_000010.10:g.96453099A>G, NC_000010.11:g.94693342A>G, NG_008373.1:g.14849A>G, NM_000772.2:c.482-1575A>G, NM_001128925.1:c.482-1575A>G, XM_005269576.1:c.482-1575A>G, XM_005269577.1:c.482-1575A>G, rs386576905
A > G
SNP
rs2917670 NC_000016.10:g.69725060T>C, NC_000016.9:g.69758963T>C, NG_011504.1:g.6571A>G, NM_000903.2:c.7+1373A>G, NM_001025433.1:c.7+1373A>G, NM_001025434.1:c.7+1373A>G, NM_001286137.1:c.7+1373A>G, XM_005255830.1:c.7+1373A>G, rs386577181
T > C
SNP
rs2917677 NC_000016.10:g.69716946C>T, NC_000016.9:g.69750849C>T, NG_011504.1:g.14685G>A, NM_000903.2:c.303+1177G>A, NM_001025433.1:c.303+1177G>A, NM_001025434.1:c.303+1177G>A, NM_001286137.1:c.303+1177G>A, XM_005255830.1:c.303+1177G>A, rs59065774
C > T
SNP
rs3093105 NC_000019.10:g.15897578A>C, NC_000019.9:g.16008388A>C, NG_007971.2:g.5497T>G, NM_001082.4:c.34T>G, NP_001073.3:p.Trp12Gly, rs117322022
A > C
SNP
W12G
rs3093158 NC_000019.10:g.15889356C>T, NC_000019.9:g.16000166C>T, NG_007971.2:g.13719G>A, NM_001082.4:c.918+67G>A, rs58337631
C > T
SNP
rs3136516 NC_000011.10:g.46739206G>A, NC_000011.9:g.46760756G>A, NG_008953.1:g.25014G>A, NM_000506.4:c.1726-59G>A, NM_001311257.1:c.1678-59G>A, XR_428840.2:n.1588-59G>A, rs17847084, rs587776431
G > A
SNP
rs3176123 NC_000020.10:g.23027413T>G, NC_000020.11:g.23046776T>G, NG_012027.1:g.7889A>C, NM_000361.2:c.*1001A>C, rs52803184, rs56561764, rs57024847
T > G
SNP
rs3212198 NC_000020.10:g.43044362C>T, NC_000020.11:g.44415722C>T, NG_009818.1:g.64922C>T, NM_000457.4:c.648+1060C>T, NM_001030003.2:c.582+1060C>T, NM_001030004.2:c.582+1060C>T, NM_001258355.1:c.627+1060C>T, NM_001287182.1:c.573+1060C>T, NM_001287183.1:c.573+1060C>T, NM_001287184.1:c.573+1060C>T, NM_175914.4:c.582+1060C>T, NM_178849.2:c.648+1060C>T, NM_178850.2:c.648+1060C>T, XM_005260407.1:c.765+1060C>T, XM_005260407.2:c.765+1060C>T, XM_011528797.1:c.696+1060C>T, XM_011528798.1:c.696+1060C>T, rs3787357, rs57374331
C > T
SNP
rs339097 NC_000007.13:g.128399224A>G, NC_000007.14:g.128759170A>G, NG_033110.1:g.24879A>G, NM_001130674.2:c.582+133A>G, NM_001199671.1:c.606+133A>G, NM_001199672.1:c.606+133A>G, NM_001199673.1:c.582+133A>G, NM_001219.4:c.582+133A>G, NR_074086.1:n.308+133A>G, XM_011516588.1:c.360+133A>G, rs1668425, rs386582001, rs56844598
A > G
SNP
rs3756009 NC_000004.11:g.187186111A>G, NC_000004.12:g.186264957A>G, NG_008051.1:g.3994A>G, NM_000128.3:c.-1340A>G, XM_005262821.1:c.-1340A>G, XM_005262821.2:c.-1340A>G, XM_005262822.1:c.-1340A>G, XM_005262822.2:c.-1340A>G, XM_005262823.1:c.-1340A>G, XM_005262823.2:c.-1340A>G, XM_005262824.1:c.-1340A>G, XM_005262825.1:c.-1340A>G, XM_005262826.1:c.-1340A>G, XM_006714137.1:c.-1340A>G, XR_938706.1:n.-988A>G, XR_938707.1:n.-988A>G, rs17507427
A > G
SNP
rs3814637 NC_000010.10:g.96521045C>T, NC_000010.11:g.94761288C>T, NG_008384.2:g.3583C>T, NM_000769.2:c.-1418C>T, rs11565103, rs117910415, rs17878465, rs58858251
C > G
C > T
SNP
rs3815455
C > T
SNP
rs3826041
A > C
SNP
rs4124874 NC_000002.11:g.234665659T>G, NC_000002.12:g.233757013T>G, NG_002601.2:g.172270T>G, NG_033238.1:g.1741T>G, NM_001072.3:c.862-10021T>G, NM_007120.2:c.868-10021T>G, NM_019075.2:c.856-10021T>G, NM_019076.4:c.856-10021T>G, NM_019077.2:c.856-10021T>G, NM_019078.1:c.868-10021T>G, NM_019093.2:c.868-10021T>G, NM_021027.2:c.856-10021T>G, NM_205862.1:c.61-10021T>G, NR_037694.1:n.-1668A>C, NR_037695.1:n.-1668A>C, NR_037696.1:n.-1668A>C, XR_241238.1:n.924-10021T>G, XR_241240.1:n.1023-10021T>G, XR_241241.1:n.942-10021T>G, rs57409706
T > G
SNP
rs41301394
C > T
SNP
rs4148323 NC_000002.11:g.234669144G>A, NC_000002.12:g.233760498G>A, NG_002601.2:g.175755G>A, NG_033238.1:g.5226G>A, NM_000463.2:c.211G>A, NM_001072.3:c.862-6536G>A, NM_007120.2:c.868-6536G>A, NM_019075.2:c.856-6536G>A, NM_019076.4:c.856-6536G>A, NM_019077.2:c.856-6536G>A, NM_019078.1:c.868-6536G>A, NM_019093.2:c.868-6536G>A, NM_021027.2:c.856-6536G>A, NM_205862.1:c.61-6536G>A, NP_000454.1:p.Gly71Arg, XR_241238.1:n.924-6536G>A, XR_241239.1:n.233G>A, XR_241240.1:n.1023-6536G>A, XR_241241.1:n.942-6536G>A, rs113525835, rs34360183, rs58105808, rs58585123
G > A
SNP
G71R
rs4244285 NC_000010.10:g.96541616G>A, NC_000010.11:g.94781859G>A, NG_008384.2:g.24154G>A, NM_000769.1:c.681G>A, NM_000769.2:c.681G>A, NP_000760.1:p.Pro227=, rs116940633, rs17879456, rs60361278
G > A
SNP
P227P
rs429358 NC_000019.10:g.44908684T>C, NC_000019.9:g.45411941T>C, NG_007084.2:g.7903T>C, NM_000041.3:c.388T>C, NM_001302688.1:c.466T>C, NM_001302689.1:c.388T>C, NM_001302690.1:c.388T>C, NM_001302691.1:c.388T>C, NP_000032.1:p.Cys130Arg, NP_001289617.1:p.Cys156Arg, NP_001289618.1:p.Cys130Arg, NP_001289619.1:p.Cys130Arg, NP_001289620.1:p.Cys130Arg, XM_005258867.1:c.466T>C, XM_005258868.1:c.388T>C, XP_005258924.1:p.Cys156Arg, XP_005258925.1:p.Cys130Arg, rs61228756, rs630496
T > C
SNP
C130R
rs4379440
G > T
SNP
rs4645943 NC_000008.10:g.128747471C>T, NC_000008.11:g.127735225C>T, NG_007161.1:g.4156C>T, NM_002467.4:c.-1369C>T, NR_117101.1:n.-1258G>A, NR_117102.1:n.-1258G>A, XM_005250922.1:c.-1411C>T, XR_242431.1:n.-1261G>A, rs57894328
C > T
SNP
rs4645962 NC_000008.10:g.128751326T>C, NC_000008.11:g.127739080T>C, NG_007161.1:g.8011T>C, NM_002467.4:c.802+61T>C, XM_005250922.1:c.757+61T>C
T > C
SNP
rs4645974 NC_000008.10:g.128754689C>T, NC_000008.11:g.127742443C>T, NG_007161.1:g.11374C>T, rs56434981, rs59670569
C > T
SNP
rs4653436 NC_000001.10:g.225995211G>A, NC_000001.11:g.225807509G>A, NG_009776.1:g.2415G>A, rs57171465
G > A
SNP
rs4841588 NC_000008.10:g.11614225G>T, NC_000008.11:g.11756716G>T, NG_008177.2:g.84798G>T, NM_001308093.1:c.1001-219G>T, NM_001308094.1:c.380-219G>T, NM_002052.4:c.998-219G>T, XM_005272384.1:c.1001-219G>T, XM_005272385.1:c.1001-219G>T, XM_005272385.3:c.1001-219G>T, XM_005272386.1:c.1001-219G>T, XM_005272387.1:c.380-219G>T, XM_006716248.1:c.1001-219G>T, XM_006716249.2:c.380-219G>T, XM_011543817.1:c.1001-219G>T, XM_011543818.1:c.1001-219G>T, rs58157506
G > T
SNP
rs4889606 NC_000016.10:g.30999862A>G, NC_000016.9:g.31011183A>G, NG_041829.1:g.15647T>C, NM_052874.4:c.280+1066T>C, rs17641007, rs57849313
A > G
SNP
rs4917639 NC_000010.10:g.96725535A>C, NC_000010.11:g.94965778A>C, NG_008385.1:g.32121A>C, NM_000771.3:c.820-6326A>C, XM_005269575.1:c.820-6326A>C, rs17429632, rs56870279
A > C
SNP
rs4918758 NC_000010.10:g.96697252T>C, NC_000010.11:g.94937495T>C, NG_008385.1:g.3838T>C, NM_000771.3:c.-1188T>C, XM_005269575.1:c.-1188T>C, rs17110346
T > C
SNP
rs4986893 NC_000010.10:g.96540410G>A, NC_000010.11:g.94780653G>A, NG_008384.2:g.22948G>A, NM_000769.2:c.636G>A, NP_000760.1:p.Trp212Ter, rs52827375, rs57081121
G > A
SNP
W212*
rs4986910 NC_000007.13:g.99358524A>G, NC_000007.14:g.99760901A>G, NG_008421.1:g.28285T>C, NM_001202855.2:c.1331T>C, NM_017460.5:c.1334T>C, NP_001189784.1:p.Met444Thr, NP_059488.2:p.Met445Thr, XM_011515841.1:c.1427T>C, XM_011515842.1:c.1424T>C, XP_011514143.1:p.Met476Thr, XP_011514144.1:p.Met475Thr, rs386597005, rs60835115
A > G
SNP
M444T
rs510317 NC_000013.10:g.113759754A>G, NC_000013.11:g.113105440A>G, NG_009262.1:g.4650A>G, NM_000131.4:c.-402A>G, NM_001267554.1:c.-402A>G, NM_019616.3:c.-402A>G, NR_051961.1:n.-348A>G, XM_006719963.2:c.-402A>G, XM_011537474.1:c.-402A>G, XM_011537475.1:c.-402A>G, XM_011537477.1:c.-402A>G, rs10482840, rs118091088, rs1745933, rs2854147, rs36208068, rs36232712, rs59513874, rs762637
A > G
A > T
SNP
rs510335 NC_000013.10:g.113759755G>T, NC_000013.11:g.113105441G>T, NG_009262.1:g.4651G>T, NM_000131.4:c.-401G>T, NM_001267554.1:c.-401G>T, NM_019616.3:c.-401G>T, NR_051961.1:n.-347G>T, XM_006719963.2:c.-401G>T, XM_011537474.1:c.-401G>T, XM_011537475.1:c.-401G>T, XM_011537477.1:c.-401G>T, rs10482841, rs116847340, rs1755686, rs36208069, rs36232713, rs7981123
G > A
G > C
G > T
SNP
rs56165452 NC_000010.10:g.96741054T>C, NC_000010.11:g.94981297T>C, NG_008385.1:g.47640T>C, NM_000771.3:c.1076T>C, NP_000762.2:p.Ile359Thr, XM_005269575.1:c.1076T>C, XP_005269632.1:p.Ile359Thr
T > C
SNP
I359T
rs570317 NC_000019.10:g.48783974A>G, NC_000019.9:g.49287231A>G, rs837633
A > G
SNP
rs5896 NC_000011.10:g.46723453C>T, NC_000011.9:g.46745003C>T, NG_008953.1:g.9261C>T, NM_000506.4:c.494C>T, NM_001311257.1:c.446C>T, NP_000497.1:p.Thr165Met, NP_001298186.1:p.Thr149Met, XR_428840.2:n.538C>T, rs17645388, rs3136453, rs60714661
C > T
SNP
T165M
rs5985 NC_000006.11:g.6318795C>A, NC_000006.12:g.6318562C>A, NG_008107.1:g.7130G>T, NM_000129.3:c.103G>T, NP_000120.2:p.Val35Leu, XM_006715010.2:c.103G>T, XM_011514342.1:c.265G>T, XP_006715073.1:p.Val35Leu, XP_011512644.1:p.Val89Leu, rs60452761
C > A
SNP
V35L
rs6018 NC_000001.10:g.169511878T>G, NC_000001.11:g.169542640T>G, NG_011806.1:g.48892A>C, NM_000130.4:c.2450A>C, NP_000121.2:p.Asn817Thr, rs13306324, rs52823616, rs60636513
T > G
SNP
N817T
rs6046 NC_000013.10:g.113773159G>A, NC_000013.11:g.113118845G>A, NG_009258.1:g.1047G>A, NG_009262.1:g.18055G>A, NM_000131.4:c.1238G>A, NM_001267554.1:c.986G>A, NM_019616.3:c.1172G>A, NP_000122.1:p.Arg413Gln, NP_001254483.1:p.Arg329Gln, NP_062562.1:p.Arg391Gln, NR_051961.1:n.1259G>A, XM_006719963.2:c.1031G>A, XM_011537474.1:c.1280G>A, XM_011537475.1:c.1094G>A, XM_011537476.1:c.932G>A, XM_011537477.1:c.1241G>A, XP_006720026.1:p.Arg344Gln, XP_011535776.1:p.Arg427Gln, XP_011535777.1:p.Arg365Gln, XP_011535778.1:p.Arg311Gln, XP_011535779.1:p.Arg414Gln, rs112274850, rs36209568, rs532977
G > -
G > A
SNP
R413Q
rs60711313 unknown
rs61162043 NC_000016.10:g.31102913A>G, NC_000016.9:g.31114234A>G
A > G
SNP
rs61742245 NC_000016.10:g.31094624C>A, NC_000016.9:g.31105945C>A, NG_011564.1:g.5332G>T, NM_001311311.1:c.106G>T, NM_024006.4:c.106G>T, NM_024006.5:c.106G>T, NM_206824.2:c.106G>T, NP_001298240.1:p.Asp36Tyr, NP_076869.1:p.Asp36Tyr, NP_996560.1:p.Asp36Tyr, XM_005255568.1:c.106G>T, XM_011545943.1:c.106G>T, XM_011545944.1:c.106G>T, XM_011545945.1:c.106G>T, XP_005255625.1:p.Asp36Tyr, XP_011544245.1:p.Asp36Tyr, XP_011544246.1:p.Asp36Tyr, XP_011544247.1:p.Asp36Tyr, XR_243303.1:n.755G>T, XR_950848.1:n.894G>T, rs104894543
C > A
SNP
D36Y
rs699664 NC_000002.11:g.85780536C>T, NC_000002.12:g.85553413C>T, NG_011811.2:g.13122G>A, NM_000821.6:c.974G>A, NM_001142269.3:c.803G>A, NP_000812.2:p.Arg325Gln, NP_001135741.1:p.Arg268Gln, XM_005264259.1:c.974G>A, XM_005264259.3:c.974G>A, XM_011532764.1:c.152G>A, XM_011532765.1:c.152G>A, XP_005264316.1:p.Arg325Gln, XP_011531066.1:p.Arg51Gln, XP_011531067.1:p.Arg51Gln, XR_939677.1:n.1039G>A, rs116926260, rs17617541, rs386606475, rs52835631
C > T
SNP
R325Q
rs7089580 NC_000010.10:g.96705223A>T, NC_000010.11:g.94945466A>T, NG_008385.1:g.11809A>T, NM_000771.3:c.482-2313A>T, XM_005269575.1:c.482-2313A>T, rs111172059, rs58626010
A > T
SNP
rs71486745 NC_000010.10:g.96695776_96695777delGT, NC_000010.11:g.94936019_94936020delGT, NG_008385.1:g.2362_2363delGT
GT > -
indel
rs7196161 NC_000016.10:g.31099660G>A, NC_000016.9:g.31110981G>A, NG_011564.1:g.296C>T, rs17882285
G > A
SNP
rs7200749 NC_000016.10:g.31091268G>A, NC_000016.9:g.31102589G>A, NG_011564.1:g.8688C>T, NM_001311311.1:c.442C>T, NM_024006.5:c.358C>T, NM_206824.2:c.248C>T, NP_001298240.1:p.Leu148=, NP_076869.1:p.Leu120=, NP_996560.1:p.Pro83Leu, XM_005255568.1:c.442C>T, XM_011545816.1:c.-2459C>T, XM_011545817.1:c.-2459C>T, XM_011545818.1:c.-2459C>T, XM_011545819.1:c.-2459C>T, XM_011545820.1:c.-2459C>T, XM_011545943.1:c.442C>T, XM_011545944.1:c.358C>T, XM_011545945.1:c.248C>T, XP_005255625.1:p.Leu148=, XP_011544245.1:p.Leu148=, XP_011544246.1:p.Leu120=, XP_011544247.1:p.Pro83Leu, XR_243303.1:n.907C>T, XR_950848.1:n.1146C>T, rs17881770, rs59562965
G > A
SNP
L148L
rs72547529 NC_000016.10:g.31093399C>T, NC_000016.9:g.31104720C>T, NG_011564.1:g.6557G>A, NM_001311311.1:c.196G>A, NM_024006.5:c.196G>A, NM_206824.2:c.173+1158G>A, NP_001298240.1:p.Val66Met, NP_076869.1:p.Val66Met, XM_005255568.1:c.196G>A, XM_011545943.1:c.196G>A, XM_011545944.1:c.196G>A, XM_011545945.1:c.173+1158G>A, XP_005255625.1:p.Val66Met, XP_011544245.1:p.Val66Met, XP_011544246.1:p.Val66Met, XR_243303.1:n.823-78G>A, XR_950848.1:n.984G>A
C > T
SNP
V66M
rs72558187 NC_000010.10:g.96701715T>C, NC_000010.11:g.94941958T>C, NG_008385.1:g.8301T>C, NM_000771.3:c.269T>C, NP_000762.2:p.Leu90Pro, XM_005269575.1:c.269T>C, XP_005269632.1:p.Leu90Pro, rs74052158
T > C
SNP
L90P
rs72558189 NC_000010.10:g.96701991G>A, NC_000010.11:g.94942234G>A, NG_008385.1:g.8577G>A, NM_000771.3:c.374G>A, NP_000762.2:p.Arg125His, XM_005269575.1:c.374G>A, XP_005269632.1:p.Arg125His, rs73994288
G > A
SNP
R125H
rs72800847
G > A
SNP
rs7294 NC_000016.10:g.31091000C>T, NC_000016.9:g.31102321C>T, NG_011564.1:g.8956G>A, NM_001311311.1:c.*134G>A, NM_024006.5:c.*134G>A, NM_206824.2:c.*237G>A, XM_005255568.1:c.*134G>A, XM_011545816.1:c.-2191G>A, XM_011545817.1:c.-2191G>A, XM_011545818.1:c.-2191G>A, XM_011545819.1:c.-2191G>A, XM_011545820.1:c.-2191G>A, XM_011545943.1:c.*134G>A, XM_011545944.1:c.*134G>A, XM_011545945.1:c.*237G>A, XR_243303.1:n.1175G>A, XR_950848.1:n.1414G>A, rs17880624, rs59098562
C > T
SNP
rs7412 NC_000019.10:g.44908822C>T, NC_000019.9:g.45412079C>T, NG_007084.2:g.8041C>T, NM_000041.3:c.526C>T, NM_001302688.1:c.604C>T, NM_001302689.1:c.526C>T, NM_001302690.1:c.526C>T, NM_001302691.1:c.526C>T, NP_000032.1:p.Arg176Cys, NP_001289617.1:p.Arg202Cys, NP_001289618.1:p.Arg176Cys, NP_001289619.1:p.Arg176Cys, NP_001289620.1:p.Arg176Cys, XM_005258867.1:c.604C>T, XM_005258868.1:c.526C>T, XP_005258924.1:p.Arg202Cys, XP_005258925.1:p.Arg176Cys, rs3200542
C > T
SNP
R176C
rs749671 NC_000016.10:g.31077026G>A, NC_000016.9:g.31088347G>A, NM_014699.3:c.702G>A, NP_055514.3:p.Glu234=, XM_005255710.1:c.702G>A, XM_005255710.2:c.702G>A, XM_005255711.1:c.702G>A, XM_005255711.2:c.702G>A, XM_005255712.1:c.702G>A, XM_005255712.2:c.702G>A, XM_011545990.1:c.702G>A, XP_005255767.1:p.Glu234=, XP_005255768.1:p.Glu234=, XP_005255769.1:p.Glu234=, XP_011544292.1:p.Glu234=, rs17846139, rs17859147, rs386610694
G > A
SNP
E234E
rs7542281 NC_000001.10:g.169536439C>T, NC_000001.11:g.169567201C>T, NG_011806.1:g.24331G>A, NM_000130.4:c.373+5020G>A, rs9332558
C > T
SNP
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
rs7856096 NC_000009.11:g.130566539A>G, NC_000009.12:g.127804260A>G, NG_023245.1:g.6386A>G, NM_001018078.2:c.-12-25A>G, NM_001288803.1:c.139-25A>G, NM_004957.5:c.139-25A>G, NR_110170.1:n.206-25A>G, XM_005251863.1:c.139-25A>G, XM_005251864.1:c.139-25A>G, XM_005251864.2:c.139-25A>G, XM_005251865.1:c.-387A>G, XM_011518437.1:c.-37A>G, XM_011518438.1:c.-12-25A>G, XR_242581.1:n.165-25A>G, XR_242581.2:n.184-25A>G, XR_242582.1:n.165-25A>G, XR_242582.2:n.184-25A>G, rs57202884
A > G
SNP
rs7900194 NC_000010.10:g.96702066G>A, NC_000010.11:g.94942309G>A, NG_008385.1:g.8652G>A, NM_000771.3:c.449G>A, NP_000762.2:p.Arg150His, XM_005269575.1:c.449G>A, XP_005269632.1:p.Arg150His, rs57530584
G > A
SNP
R150H
rs8050894 NC_000016.10:g.31093188C>G, NC_000016.9:g.31104509C>G, NG_011564.1:g.6768G>C, NM_001311311.1:c.283+124G>C, NM_024006.5:c.283+124G>C, NM_206824.2:c.173+1369G>C, XM_005255568.1:c.283+124G>C, XM_011545943.1:c.283+124G>C, XM_011545944.1:c.283+124G>C, XM_011545945.1:c.173+1369G>C, XR_243303.1:n.832+124G>C, XR_950848.1:n.1071+124G>C, rs17886369
C > G
C > T
SNP
rs8175347
(TA)6 > (TA)5
(TA)6 > (TA)7
(TA)6 > (TA)8
microsatellite
rs8178607 NC_000003.11:g.93653992G>A, NC_000003.12:g.93935148G>A, NG_009813.1:g.43943C>T, NM_000313.3:c.77-7741C>T, NM_001314077.1:c.77-6351C>T, XM_005247626.1:c.77-6351C>T, XM_005247626.3:c.77-6351C>T, rs386615972, rs58324054
G > A
SNP
rs887829 NC_000002.11:g.234668570C>T, NC_000002.12:g.233759924C>T, NG_002601.2:g.175181C>T, NG_033238.1:g.4652C>T, NM_000463.2:c.-364C>T, NM_001072.3:c.862-7110C>T, NM_007120.2:c.868-7110C>T, NM_019075.2:c.856-7110C>T, NM_019076.4:c.856-7110C>T, NM_019077.2:c.856-7110C>T, NM_019078.1:c.868-7110C>T, NM_019093.2:c.868-7110C>T, NM_021027.2:c.856-7110C>T, NM_205862.1:c.61-7110C>T, XR_241238.1:n.924-7110C>T, XR_241239.1:n.-342C>T, XR_241240.1:n.1023-7110C>T, XR_241241.1:n.942-7110C>T, rs12990609, rs34790730, rs36207722, rs386619532, rs61315639
C > T
SNP
rs9332092
T > C
SNP
rs9332096 NC_000010.10:g.96696875C>T, NC_000010.11:g.94937118C>T, NG_008385.1:g.3461C>T, NM_000771.3:c.-1565C>T, XM_005269575.1:c.-1565C>T
C > T
SNP
rs9332098
G > A
SNP
rs9332127 NC_000010.10:g.96707471G>C, NC_000010.11:g.94947714G>C, NG_008385.1:g.14057G>C, NM_000771.3:c.482-65G>C, XM_005269575.1:c.482-65G>C, rs17847038, rs58304507
G > C
SNP
rs9332131 NC_000010.10:g.96709039delA, NC_000010.11:g.94949282delA, NG_008385.1:g.15625delA, NM_000771.3:c.817delA, NP_000762.2:p.Lys273Argfs, XM_005269575.1:c.817delA, XP_005269632.1:p.Lys273Argfs
A > -
indel
K273R
rs9332197 NC_000010.10:g.96740908T>C, NC_000010.11:g.94981151T>C, NG_008385.1:g.47494T>C, NM_000771.3:c.962-32T>C, XM_005269575.1:c.962-32T>C, rs60905497
T > C
SNP
rs9332238 NC_000010.10:g.96748492G>A, NC_000010.11:g.94988735G>A, NG_008385.1:g.55078G>A, NM_000771.3:c.1292-112G>A, XM_005269575.1:c.1275-731G>A
G > A
SNP
rs9923231 NC_000016.10:g.31096368C=, NC_000016.10:g.31096368C>T, NC_000016.9:g.31107689C=, NC_000016.9:g.31107689C>T, NG_011564.1:g.3588G=, NG_011564.1:g.3588G>A, NM_001311311.1:c.-1639G=, NM_001311311.1:c.-1639G>A, NM_024006.5:c.-1639G=, NM_024006.5:c.-1639G>A, NM_206824.2:c.-1639G=, NM_206824.2:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_005255568.1:c.-1639G>A, XM_011545943.1:c.-1639G=, XM_011545943.1:c.-1639G>A, XM_011545944.1:c.-1252G=, XM_011545944.1:c.-1252G>A, XM_011545945.1:c.-1252G=, XM_011545945.1:c.-1252G>A, XR_243303.1:n.-990G=, XR_243303.1:n.-990G>A, XR_950848.1:n.-31G=, XR_950848.1:n.-31G>A, rs117572127, rs17878363, rs60511154
C > A
C > G
C > T
SNP
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Warfarin sodium
Trade Names
  • Athrombin
  • Athrombin-K
  • Athrombine-K
  • Brumolin
  • Co-Rax
  • Coumadin
  • Coumadin Tabs
  • Coumafen
  • Coumafene
  • Coumaphen
  • Coumaphene
  • Coumarins
  • Coumefene
  • D-Con
  • Dethmor
  • Dethnel
  • Dicusat E
  • Frass-Ratron
  • Jantoven
  • Kumader
  • Kumadu
  • Kumatox
  • Kypfarin
  • Latka 42
  • Mar-Frin
  • Marevan
  • Maveran
  • Panwarfin
  • Place-Pax
  • Prothromadin
  • RAX
  • Rosex
  • Sofarin
  • Solfarin
  • Sorexa Plus
  • Temus W
  • Tintorane
  • Tox-Hid
  • Vampirinip II
  • Vampirinip III
  • Waran
  • Warf 42
  • Warfarat
  • Warfarin Plus
  • Warfarin Q
  • Warfarine
  • Warficide
  • Warfilone
  • Zoocoumarin
Brand Mixture Names

PharmGKB Accession Id

PA451906

Type(s):

Drug

Description

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Source: Drug Bank

Pharmacogenetics

Warfarin is one of the most widely prescribed anticoagulant drugs worldwide. It is used to prevent thromboembolic diseases in patients with deep vein thrombosis, atrial fibrillation, recurrent stroke or heart valve prosthesis [Article:16960144]. Warfarin, as do other coumarin-type drugs with similar mechanisms of action, acts as an inhibitor of VKORC1; this leads to a reduced amount of Vitamin K available to serve as a cofactor for clotting proteins [Article:14765194]. Although effective, warfarin dosing is challengIng due to its narrow therapeutic index and high degree of inter-individual variability in optimal dosing (between 0.6 and 15.5 mg/day) [Articles:11926893, 12931134, 15930419, 16888441]. Inappropriate dosing of warfarin has been associated with a substantial risk of both major and minor hemorrhage [Articles:16888441, 16960144, 16983400].

Pharmacokinetics

Warfarin is a natural product and is administered as racemic mixture of the R and S stereoisomers of the drug. S-warfarin is 3-5 times more potent an inhibitor of the vitamin K epoxide reductase complex, the target of action, than R-warfarin [Article:3567019]. The stereoisomers are metabolized by different phase 1 enzymes; the predominant metabolism of the S isomer is via CYP2C9, whereas the metabolism of R-warfarin is mainly via CYP3A4 with involvement of CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C18 and CYP2C19 [Articles:1581537, 11353757, 8689941, 8723744] as depicted in the warfarin PK pathway (http://pharmgkb.org/pathway/PA145011113). Phase 2 metabolism of warfarin has not been well studied and is not depicted in this pathway representation, although it is known that sulfated and glucuronyl conjugates can be formed [Article:1732719]. Elimination is predominantly renal however warfarin has been shown to interact with the ABCB1 transporter in liver [Article:1467682].

Pharmacodynamics

Warfarin exerts its anticoagulant effect through inhibition of its target Vitamin K epoxide reductase (VKORC1) [Article:14765194]. The two enantiomers of warfarin are both able to inhibit VKORC1, although with different potencies. The mechanism of action of warfarin is depicted in the Warfarin Pharmacodynamics Pathway (http://pharmgkb.org/pathway/PA145011114). VKORC1 catalyzes the conversion of oxidized Vitamin K to reduced Vitamin K with the help of microsomal epoxide hydrolase (EPHX1). Treatment of warfarin blocks this reaction, which leads to a reduction in the pool of reduced Vitamin K that is needed as a cofactor for clotting proteins. The downstream genes influenced by the form of Vitamin K are also depicted in the pathway. The product of these target genes are postranslationally carboxylated to become Gla-containing proteins by gamma-glutamyl carboxylase (GGCX). Gla-containing proteins are involved in hemostasis (coagulation factors F2, F7, F9, F10, Protein C, S and Z) as well as bone metabolism (BGLAP), tissue matrix (MGP) and apoptosis (GAS6) [Articles:16983400, 18752379, 18698879]. The endoplasmic reticulum chaperone protein calumenin (CALU ) can bind to the vitamin K cycle and inhibit its activity [Article:15075329].

Pharmacogenetics

Warfarin pharmacogenetics is considered a classical example of pharmacogenetics. Many studies have attempted to explain the factors that influence warfarin response [Articles:16722840, 16960144, 17161452]. Candidate genes from both the PK and PD pathways have been the subjects of investigation for their potential pharmacogenetic relevance. Overall, VKORC1 polymorphisms account for ~30% of the variance in stabilized warfarin dose and many studies have consistently demonstrated that VKORC1 genotype appears to be the single biggest predictor of warfarin dose [Articles:20203262, 19228618, 17161452, 18535201, 18574025, 18183038]. About 40% of dose variance could be explained taking into consideration both VKORC1 and CYP2C9 genetic polymorphisms. Accounting for genetic variation in both VKORC1 and CYP2C9, age, height, body weight, interacting drugs, and indication for warfarin therapy explained about 55% of the variability in warfarin dose [Article:17042764]. Many studies have attempted to define a warfarin dosing algorithm that takes into account both genetic and non-genetic factors in order to predict an optimal warfarin dose [Articles:19228618, 17042764, 18305455]. An online warfarin dosing algorithm is available online at http://www.warfarindosing.org/Source/Home.aspx to help doctors and other clinicians begin warfarin therapy by estimating the therapeutic dose in patients new to warfarin. In 2007, pharmacogenomic information for warfarin was approved by FDA to be included in the product label stating that VKORC1 and CYP2C9 genotypes may be useful in determining the optimal initial dose of warfarin [Article:17906972]. The warfarin label was updated again in 2010 to include specific CYP2C9 and VKORC1 variant information and a summary table describing the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants (http://www.pharmgkb.org/clinical/10879145.pdf). Genetic testing was recommended by FDA prior to initiating treatment with warfarin (http://pharmgkb.org/drug/PA451906#tabview=tab0&subtab=32).

The 3 most important variants shown to have clinical implications for warfarin dosing and prevention of adverse events are the G-1639A polymorphism (rs9923231) of VKORC1 and *2 (rs1799853), *3 (rs1057910) alleles of CYP2C9. The VKORC1:G-1639A polymorphism is a polymorphism in the promoter region of VKORC1 and associated with lower dose requirements for warfarin in Caucasian and Asian patients [Articles:15888487, 18305455, 20203262, 19228618, 17161452, 18535201, 18574025, 18183038]. Individuals with the CYP2C9*2 and *3 variants are more likely to need lower doses of warfarin, take a longer time to reach target INR on starting warfarin therapy and have an increased risk of bleeding complications [Articles:10073515, 11926893]. Several other polymorphisms in CYP2C9 have been reported some of which have also been shown to effect warfarin metabolism (*4, [Article:12621390]; *5, [Article:11455026]; *11, [Article:15970795]). A variant of CYP4F2 (rs2108622) has been shown to be associated with warfarin dose [Article:18250228]. Recently, a new variant (rs339097) in VKORC1 regulator gene calumenin (CALU) has been identified that predicts higher warfarin dose in African Americans populations, with the G allele of (rs339097) associated with 14.5% higher therapeutic warfarin dose [Article:20200517]. Further information on variants affecting warfarin response is available on the warfarin PGx research page (http://pharmgkb.org/drug/PA451906#tabview=tab1&subtab=32).

Source: PharmGKB

Indication

For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Warfarin inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.

Source: Drug Bank

Pharmacology

Warfarin, a coumarin anticoagulant, is a racemic mixture of two active isomers. It is used in the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).

Source: Drug Bank

Food Interaction

Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables).|Avoid alcohol.|Limit garlic, ginger, gingko, and horse chestnut.|Avoid St. John's Wort.|Avoid drastic changes in dietary habit.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Metabolized stereo- and regio-selectively by hepatic microsomal enzymes. S-warfarin is predominantly metabolized by cytochrome P450 (CYP) 2C9 to yield the 6- and 7-hydroxylated metabolites. R-warfarin is metabolized by CYP1A1, 1A2, and 3A4 to yield 6-, 8-, and 10-hydroxylated metabolites. Hydroxylated metabolites may be further conjugated prior to excretion into bile and urine. UGT1A1 appears to be responsible for producing the 6-O-glucuronide of warfarin, with a possibly contribution from UGT1A10. Five UGT1As may be involved in the formation of 7-O-glucuronide warfarin. S-warfarin has higher potency than R-warfarin and genetic polymorphisms in CYP2C9 may dramatically decrease clearance of and increase toxicity of the medication.

Source: Drug Bank

Protein Binding

99% bound primarily to albumin

Source: Drug Bank

Absorption

Rapidly absorbed following oral administration with considerable interindividual variations. Also absorbed percutaneously.

Source: Drug Bank

Half-Life

R-warfarin t ~1/2~=37-89 hours; S-warfarin t ~1/2~=21-43 hours.

Source: Drug Bank

Toxicity

LD ~50~=374 (orally in mice)

Source: Drug Bank

Clearance

* 0.065 +/- 0.025 mL/min/kg [CYP2C9 Genotype *1/*1] * 0.041 +/- 0.021 [CYP2C9 Genotype *1/*2 or *1/*3] * 0.020 +/- 0.011 [CYP2C9 Genotype *2/*2, *2/*3, or *3/*3]

Source: Drug Bank

Route of Elimination

The elimination of warfarin is almost entirely by metabolism. Very little warfarin is excreted unchanged in urine. The metabolites are principally excreted into the urine; and to a lesser extent into the bile.

Source: Drug Bank

Volume of Distribution

* 0.14 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C19H16O4

Source: Drug Bank

Isomeric SMILES

CC(=O)CC(c1ccccc1)c2c(c3ccccc3oc2=O)O

Source: OpenEye

Canonical SMILES

CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2

Source: Drug Bank

Average Molecular Weight

308.3279

Source: Drug Bank

Monoisotopic Molecular Weight

308.104859

Source: Drug Bank

SMILES

CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2

Source: Drug Bank

InChI String

InChI=1/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Warfarin Pathway, Pharmacodynamics
    Simplified diagram of the target of warfarin action and downstream genes and effects.
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
F2 (source: Drug Bank )
VKORC1 (source: Drug Bank )
VKORC1L1 (source: Drug Bank )

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acenocoumarol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinidine
EvidenceDrug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vitamin K

Drug Interactions

Interaction Description
acetaminophen - warfarin Acetaminophen increases the anticoagulant effect (source: Drug Bank )
allopurinol - warfarin Allopurinol increases the anticoagulant effect (source: Drug Bank )
allopurinol - warfarin Allopurinol may increase the anticoagulant effect of warfarin. (source: Drug Bank )
aminoglutethimide - warfarin The agent decreases the anticoagulant effect (source: Drug Bank )
aminoglutethimide - warfarin Aminoglutethimide may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
amiodarone - warfarin Increases the anticoagulant effect (source: Drug Bank )
amiodarone - warfarin Amiodarone may increase the anticoagulant effect of warfarin. (source: Drug Bank )
ampicillin - warfarin The IV penicillin increases the anticoagulant effect (source: Drug Bank )
amprenavir - warfarin Increases the anticoagulant effect (source: Drug Bank )
amprenavir - warfarin Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration. (source: Drug Bank )
aprepitant - warfarin Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration. (source: Drug Bank )
aspirin - warfarin The salicylate increases the effect of anticoagulant (source: Drug Bank )
aspirin - warfarin Acetylsalicylic acid increases the effect of the anticoagulant, warfarin. (source: Drug Bank )
atazanavir - warfarin The protease inhibitor increases the anticoagulant effect (source: Drug Bank )
atazanavir - warfarin The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
azithromycin - warfarin Increases the anticoagulant effect (source: Drug Bank )
azithromycin - warfarin Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration. (source: Drug Bank )
betamethasone - warfarin The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
bosentan - warfarin Increases the anticoagulant effect (source: Drug Bank )
bosentan - warfarin Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism. (source: Drug Bank )
capecitabine - warfarin The antineoplastic agent increases the anticoagulant effect (source: Drug Bank )
capecitabine - warfarin Capecitabine may increase the anticoagulant effect of warfarin by increasing its serum concentration. (source: Drug Bank )
carbamazepine - warfarin Decreases the anticoagulant effect (source: Drug Bank )
carbamazepine - warfarin Carbamazepine may decrease the anticoagulant effect of warfarin by decreasing its serum concentration. (source: Drug Bank )
carbenicillin - warfarin The IV penicillin increases the anticoagulant effect (source: Drug Bank )
cefotetan - warfarin The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
cefoxitin - warfarin The cephalosporin increases the anticoagulant effect (source: Drug Bank )
cefoxitin - warfarin The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
celecoxib - warfarin Increases the anticoagulant effect (source: Drug Bank )
celecoxib - warfarin Celecoxib may increase the anticoagulant effect of warfarin. (source: Drug Bank )
chloramphenicol - warfarin Increases the anticoagulant effect (source: Drug Bank )
cholestyramine - warfarin The gastro-intestinal binding agent decreases the anticoagulant effect (source: Drug Bank )
cholestyramine - warfarin The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption. (source: Drug Bank )
cimetidine - warfarin The anti-H2 increases the anticoagulant effect (source: Drug Bank )
cimetidine - warfarin Cimetidine may increase the anticoagulant effect of warfarin. (source: Drug Bank )
ciprofloxacin - warfarin The quinolone increases the anticoagulant effect (source: Drug Bank )
ciprofloxacin - warfarin The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
cisapride - warfarin Increases the anticoagulant effect (source: Drug Bank )
cisapride - warfarin Cisapride may increase the anticoagulant effect of warfarin. (source: Drug Bank )
citalopram - warfarin The SSRI increases the effect of anticoagulant (source: Drug Bank )
citalopram - warfarin The SSRI, citalopram, increases the effect of anticoagulant, warfarin. (source: Drug Bank )
clarithromycin - warfarin The macrolide increases anticoagulant effect (source: Drug Bank )
clarithromycin - warfarin The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
clofibrate - warfarin The fibrate increases the anticoagulant effect (source: Drug Bank )
clofibrate - warfarin The fibrate increases the anticoagulant effect (source: Drug Bank )
cloxacillin - warfarin The IV penicillin increases the anticoagulant effect (source: Drug Bank )
colestipol - warfarin The gastro-intestinal binding agent decreases the anticoagulant effect (source: Drug Bank )
colestipol - warfarin The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption. (source: Drug Bank )
danazol - warfarin The androgen, danazol, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
demeclocycline - warfarin The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
dexamethasone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank )
dexamethasone - warfarin The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
dextrothyroxine - warfarin The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin. (source: Drug Bank )
diclofenac - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
diclofenac - warfarin The NSAID, diclofenac, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
dicloxacillin - warfarin Dicloxacillin may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
diflunisal - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
diflunisal - warfarin The NSAID, diflunisal, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
disulfiram - warfarin Increases the anticoagulant effect (source: Drug Bank )
disulfiram - warfarin Disulfiram may increase the anticoagulant effect of warfarin. (source: Drug Bank )
doxycycline - warfarin The tetracycline increases the anticoagulant effect (source: Drug Bank )
doxycycline - warfarin The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
erythromycin - warfarin The macrolide increases anticoagulant effect (source: Drug Bank )
erythromycin - warfarin The macrolide, erythromycin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
ethacrynic acid - warfarin Ethacrynic acid increases the anticoagulant effect (source: Drug Bank )
ethchlorvynol - warfarin Ethchlorvynol may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
ethinyl estradiol - warfarin Increased thrombotic risk due to estrogen (source: Drug Bank )
ethinyl estradiol - warfarin Increased thrombotic risk due to estrogen (source: Drug Bank )
etodolac - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
etodolac - warfarin The NSAID, etodolac, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
etoricoxib - warfarin Etoricoxib may increase the anticoagulant effect of warfarin. (source: Drug Bank )
fenofibrate - warfarin The fibrate increases the anticoagulant effect (source: Drug Bank )
fenofibrate - warfarin Fenofibrate may increase the anticoagulant effect of warfarin. (source: Drug Bank )
fenoprofen - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
fenoprofen - warfarin The NSAID, fenoprofen, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
fluconazole - warfarin Increases the anticoagulant effect (source: Drug Bank )
fluconazole - warfarin Fluconazole may increase the serum concentration of warfarin by decreasing its metabolism. (source: Drug Bank )
fludrocortisone - warfarin The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
fluorouracil - warfarin The antineoplasic agent increases the anticoagulant effect (source: Drug Bank )
fluorouracil - warfarin The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
fluoxetine - warfarin The SSRI increases the effect of anticoagulant (source: Drug Bank )
fluoxetine - warfarin The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin. (source: Drug Bank )
fluoxymesterone - warfarin The androgen, fluoxymesterone, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
flurbiprofen - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
flurbiprofen - warfarin The NSAID, flurbiprofen, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
flutamide - warfarin Flutamide increases the anticoagulant effect (source: Drug Bank )
fluvastatin - warfarin The statin increases the anticoagulant effect (source: Drug Bank )
fluvastatin - warfarin The statin increases the anticoagulant effect (source: Drug Bank )
fosamprenavir - warfarin The protease inhibitor increases the anticoagulant effect (source: Drug Bank )
fosamprenavir - warfarin The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
fosphenytoin - warfarin Increased hydantoin levels and risk of bleeding (source: Drug Bank )
gatifloxacin - warfarin Gatifloxacin increases the anticoagulant effect (source: Drug Bank )
gefitinib - warfarin Gefitinib increases the anticoagulant effect (source: Drug Bank )
gefitinib - warfarin Gefitinib may increase the anticoagulant effect of warfarin. (source: Drug Bank )
gemfibrozil - warfarin Gemfibrozil increases the anticoagulant effect (source: Drug Bank )
gemfibrozil - warfarin Gemfibrozil may increase the anticoagulant effect of warfarin. (source: Drug Bank )
ginkgo biloba - warfarin Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. (source: Drug Bank )
glutethimide - warfarin Glutethimide may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
griseofulvin - warfarin Griseofulvin decreases the anticoagulant effect (source: Drug Bank )
griseofulvin - warfarin Griseofulvin may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
hydrocortisone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank )
hydrocortisone - warfarin The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
ibuprofen - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
ibuprofen - warfarin The NSAID, ibuprofen, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
imatinib - warfarin Imatinib increases the anticoagulant effect (source: Drug Bank )
imatinib - warfarin Imatinib may increase the anticoagulant effect of warfarin. Imatinib may increase the serum concentration of warfarin by decreasing its metabolism. (source: Drug Bank )
indinavir - warfarin The protease inhibitor increases the anticoagulant effect (source: Drug Bank )
indinavir - warfarin The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
indomethacin - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
indomethacin - warfarin The NSAID, indomethacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
isoniazid - warfarin The agent increases the effect of anticoagulant (source: Drug Bank )
isoniazid - warfarin Isoniazid may increase the anticoagulant effect of warfarin. (source: Drug Bank )
itraconazole - warfarin The imidazole increases the effect of the anticoagulant (source: Drug Bank )
itraconazole - warfarin Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. (source: Drug Bank )
ketoconazole - warfarin The imidazole increases the effect of the anticoagulant (source: Drug Bank )
ketoconazole - warfarin Ketoconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. (source: Drug Bank )
ketoprofen - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
ketoprofen - warfarin The NSAID, ketoprofen, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
ketorolac - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
ketorolac - warfarin The NSAID, ketorolac, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
leflunomide - warfarin Leflunomide increases the anticoagulant effect (source: Drug Bank )
leflunomide - warfarin Leflunomide may increase the anticoagulant effect of warfarin. (source: Drug Bank )
levamisole - warfarin The agent increases the anticoagulant effect (source: Drug Bank )
levamisole - warfarin Levamisole may increase the anticoagulant effect of warfarin. (source: Drug Bank )
levofloxacin - warfarin The quinolone increases the anticoagulant effect (source: Drug Bank )
levofloxacin - warfarin The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
levothyroxine - warfarin Thyroid hormones increase the anticoagulant effect (source: Drug Bank )
levothyroxine - warfarin The thyroid hormone, levothyroxine, increase the anticoagulant effect of warfarin. (source: Drug Bank )
lovastatin - warfarin The statin increases the anticoagulant effect (source: Drug Bank )
lovastatin - warfarin The statin increases the anticoagulant effect (source: Drug Bank )
lumiracoxib - warfarin Lumiracoxib may increase the anticoagulant effect of warfarin. (source: Drug Bank )
medroxyprogesterone - warfarin The agent increases the effect of anticoagulant (source: Drug Bank )
medroxyprogesterone - warfarin Medroxyprogesterone may increase the anticoagulant effect of warfarin. (source: Drug Bank )
mefenamic acid - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
mefenamic acid - warfarin The NSAID, mefanamic acid, may increase the anticoagulant effect warfarin. (source: Drug Bank )
mefloquine - warfarin Mefloquine can increase the anticoagulant effect (source: Drug Bank )
mefloquine - warfarin Mefloquine may increase the anticoagulant effect of warfarin. (source: Drug Bank )
meloxicam - warfarin Meloxicam increases the anticoagulant effect (source: Drug Bank )
meloxicam - warfarin Meloxicam may increase the anticoagulant effect of warfarin. (source: Drug Bank )
methimazole - warfarin The antithyroid agent causes variations in the anticoagulant effect (source: Drug Bank )
methimazole - warfarin The antithyroid agent, methimazole, may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
metronidazole - warfarin Metronidazole increases the anticoagulant effect (source: Drug Bank )
metronidazole - warfarin Metronidazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. (source: Drug Bank )
miconazole - warfarin Vaginal miconazole increases the anticoagulant effect (source: Drug Bank )
miconazole - warfarin Miconazole may increase the serum concentration of warfarin by decreasing its metabolism. (source: Drug Bank )
minocycline - warfarin The tetracycline increases the anticoagulant effect (source: Drug Bank )
minocycline - warfarin The tetracycline, minocycline, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
mitotane - warfarin Mitotane may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
moxifloxacin - warfarin Moxifloxacin increases the anticoagulant effect (source: Drug Bank )
moxifloxacin - warfarin The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
nabumetone - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
nabumetone - warfarin The NSAID, nabumetone, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
nalidixic acid - warfarin The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
naproxen - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
naproxen - warfarin The NSAID, naproxen, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
nelfinavir - warfarin The protease inhibitor increases the anticoagulant effect (source: Drug Bank )
nelfinavir - warfarin The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
nevirapine - warfarin Nevirapine decreases the anticoagulant effect (source: Drug Bank )
nevirapine - warfarin Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4. (source: Drug Bank )
norfloxacin - warfarin The quinolone increases the anticoagulant effect (source: Drug Bank )
norfloxacin - warfarin The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
ofloxacin - warfarin The quinolone increases the anticoagulant effect (source: Drug Bank )
ofloxacin - warfarin The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
orlistat - warfarin Orlistat increases the anticoagulant effect (source: Drug Bank )
orlistat - warfarin Orlistat may increase the anticoagulant effect of warfarin. (source: Drug Bank )
oxaprozin - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
oxaprozin - warfarin The NSAID, oxaprozin, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
oxyphenbutazone - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
oxyphenbutazone - warfarin The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
penicillin g - warfarin The IV penicillin increases the anticoagulant effect (source: Drug Bank )
pentoxifylline - warfarin Pentoxifylline increases the anticoagulant effect (source: Drug Bank )
pentoxifylline - warfarin Pentoxifylline may increase the anticoagulant effect of warfarin. (source: Drug Bank )
phenobarbital - warfarin The barbiturate decreases the anticoagulant effect (source: Drug Bank )
phenobarbital - warfarin The barbiturate, phenobarbital, decreases the anticoagulant effect of warfarin. (source: Drug Bank )
phenylbutazone - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
phenylbutazone - warfarin The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
phenytoin - warfarin Increased hydantoin levels and risk of bleeding (source: Drug Bank )
phenytoin - warfarin Increased hydantoin levels and risk of bleeding (source: Drug Bank )
piperacillin - warfarin The IV penicillin increases the anticoagulant effect (source: Drug Bank )
piroxicam - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
piroxicam - warfarin The NSAID, piroxicam, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
prednisolone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank )
prednisolone - warfarin The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
prednisone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank )
prednisone - warfarin The corticosteroid, prednisone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
primidone - warfarin The barbiturate decreases the anticoagulant effect (source: Drug Bank )
primidone - warfarin The barbiturate, primidone, decreases the anticoagulant effect of warfarin. (source: Drug Bank )
propafenone - warfarin The agent increases the effect of anticoagulant (source: Drug Bank )
propafenone - warfarin Propafenone may increase the anticoagulant effect of warfarin. (source: Drug Bank )
propoxyphene - warfarin Propoxyphene increases the anticoagulant effect (source: Drug Bank )
propoxyphene - warfarin Propoxyphene may increase the anticoagulant effect of warfarin. (source: Drug Bank )
propylthiouracil - warfarin The anti-thyroid agent causes variations in the anticoagulant effect (source: Drug Bank )
propylthiouracil - warfarin The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of warfarin. (source: Drug Bank )
quinidine - warfarin Quinine/quinidine increases the anticoagulant effect (source: Drug Bank )
quinidine - warfarin Quinidine may increase the anticoagulant effect of warfarin. (source: Drug Bank )
quinine - warfarin Quinine/quinidine increases the anticoagulant effect (source: Drug Bank )
quinine - warfarin Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9. (source: Drug Bank )
ranitidine - warfarin The anti-H2 increases the anticoagulant effect (source: Drug Bank )
ranitidine - warfarin Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence) (source: Drug Bank )
rifabutin - warfarin The rifamycin decreases the anticoagulant effect (source: Drug Bank )
rifabutin - warfarin Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism. (source: Drug Bank )
rifampin - warfarin The rifamycin decreases the anticoagulant effect (source: Drug Bank )
rifampin - warfarin Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism. (source: Drug Bank )
sulindac - warfarin The NSAID, sulindac, may increase the anticoagulant effect of warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
tamoxifen - warfarin Tamoxifen may increase the serum concentration of Warfarin increasing the risk of bleeding. Concomitant therapy should be avoided. (source: Drug Bank )
tamoxifen - warfarin Tamoxifen may increase the serum concentration of Warfarin increasing the risk of bleeding. Concomitant therapy should be avoided. (source: Drug Bank )
telithromycin - warfarin Telithromycin increases the anticoagulant effect (source: Drug Bank )
telithromycin - warfarin Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy. (source: Drug Bank )
tenoxicam - warfarin The NSAID increases the anticoagulant effect (source: Drug Bank )
tenoxicam - warfarin The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin. (source: Drug Bank )
testolactone - warfarin The androgen, Testolactone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testolactone is initiated, discontinued or dose changed. (source: Drug Bank )
testosterone - warfarin The androgen increases the anticoagulant effect (source: Drug Bank )
testosterone - warfarin The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed. (source: Drug Bank )
testosterone propionate - warfarin The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed. (source: Drug Bank )
tetracycline - warfarin The tetracycline increases the anticoagulant effect (source: Drug Bank )
tetracycline - warfarin Tetracycline may increase the anticoagulant effect of warfarin. (source: Drug Bank )
thiopental - warfarin Thiopental may increase the metabolism of the Vitamin K antagonist, Warfarin. Warfarin dose adjustment may be required. (source: Drug Bank )
thiopental - warfarin Thiopental may increase the metabolism of the Vitamin K antagonist, Warfarin. Warfarin dose adjustment may be required. (source: Drug Bank )
tiaprofenic acid - warfarin Increased risk of bleeding. (source: Drug Bank )
ticlopidine - warfarin Increased bleeding risk. Monitor INR. (source: Drug Bank )
tigecycline - warfarin Tigecycline may increase the serum concentration of warfarin. (source: Drug Bank )
tolbutamide - warfarin Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Warfarin. Consider alternate therapy or monitor for changes in Warfarin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank )
tolbutamide - warfarin Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Warfarin. Consider alternate therapy or monitor for changes in Warfarin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank )
tolmetin - warfarin Increased risk of bleeding. Monitor for signs and symptoms of bleeding. (source: Drug Bank )
trazodone - warfarin Trazodone decreases the anticoagulant effect (source: Drug Bank )
trazodone - warfarin Trazodone decreases the anticoagulant effect (source: Drug Bank )
treprostinil - warfarin The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy. (source: Drug Bank )
triamcinolone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank )
triamcinolone - warfarin The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
trimetrexate - warfarin The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use. (source: Drug Bank )
trimetrexate - warfarin The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use. (source: Drug Bank )
warfarin - allopurinol Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - aminoglutethimide Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - amiodarone Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - amobarbital Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - bezafibrate Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - butabarbital Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - butalbital Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - capecitabine Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect. (source: Drug Bank )
warfarin - carbamazepine Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - cimetidine Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - clopidogrel Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - danazol Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - delavirdine Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - desogestrel Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - diclofenac The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - diflunisal The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - drospirenone Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - ethynodiol diacetate Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose (source: Drug Bank )
warfarin - etodolac The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - etonogestrel Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - fenofibrate Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - fenoprofen The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - floxuridine Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - fluconazole Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - fluorouracil Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - fluoxymesterone Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - flurbiprofen Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - gemfibrozil Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - ginseng Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided. (source: Drug Bank )
warfarin - glutethimide Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - ibuprofen Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - imatinib Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - indomethacin Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - ketoprofen The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - ketorolac The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - levonorgestrel Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - levothyroxine Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - liothyronine Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - liotrix Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - medroxyprogesterone Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - meloxicam The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - mestranol Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - methimazole Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - methohexital Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - metronidazole Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - miconazole Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - nabumetone The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - nafcillin Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - nandrolone Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - naproxen The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - nicardipine Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - norethindrone Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - norgestimate Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - norgestrel Norgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestrel is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - oxandrolone Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - oxaprozin The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - pentobarbital Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - phenobarbital Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - phenytoin Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy. (source: Drug Bank )
warfarin - phytonadione Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased. (source: Drug Bank )
warfarin - piroxicam Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - propylthiouracil Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - s-adenosylmethionine Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided. (source: Drug Bank )
warfarin - salicylate-sodium The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin. (source: Drug Bank )
warfarin - secobarbital Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - sucralfate Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - sulfadiazine Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - sulfamethoxazole Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - sulfinpyrazone Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding. (source: Drug Bank )
warfarin - sulfisoxazole Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - sulindac The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - tamoxifen Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk. (source: Drug Bank )
warfarin - testolactone Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - testosterone Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - thiopental Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - tolbutamide Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank )
warfarin - tolmetin The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. (source: Drug Bank )
warfarin - trisalicylate-choline The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin. (source: Drug Bank )

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Agranulocytosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alcoholism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alzheimer Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arterial Occlusive Diseases
No Dosing Guideline available DL CA No Variant Annotation available No VIP available No VIP available
Arteriosclerosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available DL CA VA No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Flutter
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood Coagulation Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Brugada syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy, Hypertrophic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cardiovascular Diseases
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Chondrodysplasia Punctata
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coagulation Protein Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colonic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coronary Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Death
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Death, Sudden, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diabetes Mellitus, Type 2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interaction with drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Embolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epidermal Necrolysis, Toxic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gilbert's syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Graft vs Host Disease
No Dosing Guideline available DL CA VA No VIP available No VIP available
Heart Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Heart Valve Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
heart valve replacement
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hematoma, Subdural
No Dosing Guideline available DL CA VA No VIP available No VIP available
Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperthyroidism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypothyroidism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
international normalized ratio variability (inr-var)
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Intracranial Hemorrhages
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malignant Hyperthermia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available DL CA VA No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myopathy, Central Core
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Necrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Osteonecrosis
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
over-anticoagulation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pancreatitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Nervous System Diseases
No Dosing Guideline available DL CA No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available DL CA No Variant Annotation available No VIP available No VIP available
Pulmonary Embolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson Syndrome
No Dosing Guideline available DL CA VA No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sudden Infant Death
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tardive dyskinesia
No Dosing Guideline available DL CA VA No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thrombolytic disease
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thyrotoxicosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time above therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time below therapeutic range
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
time in therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time to achieve stable dose
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time to therapeutic inr
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Torsades de Pointes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vascular Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
venous thromboembolism
No Dosing Guideline available DL CA No Variant Annotation available No VIP available No VIP available
Venous Thrombosis
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ventricular Fibrillation

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to warfarin: 444

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting prolonged dose titration in patients starting warfarin. Pharmacoepidemiology and drug safety. 2016. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Theory based PKPD of S- and R-warfarin and effects on INR: influence of body size, composition and genotype in cardiac surgery patients. British journal of clinical pharmacology. 2016. Xue Ling, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of Novel Variants Associated with Warfarin Stable Dosage Using a Two-stage Extreme Phenotype Strategy. Journal of thrombosis and haemostasis : JTH. 2016. Luo Zhiying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. Pharmacogenomics. 2016. Sivadas Ambily, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Cardiovascular therapeutics. 2016. Zhang Jinhua, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of variability in warfarin response after the dose-titration phase. Pharmacogenetics and genomics. 2016. Iwuchukwu Otito F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. European journal of clinical pharmacology. 2016. Zeng Wu-Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Admixture and ethno-specific alleles: missing links for global pharmacogenomics. Pharmacogenomics. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement. Pharmacogenomics. 2016. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016. Eriksson Niclas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicology and applied pharmacology. 2016. Pourgholi Leyla, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenetics and genomics. 2016. French Benjamin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation. Gene. 2016. Zhang Hongshen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2016. Wypasek E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients. Molecular diagnosis & therapy. 2016. Wakamiya Takuya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on european patients. British journal of clinical pharmacology. 2016. Gómez-Outes Antonio A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei medical journal. 2016. Cho Sun Mi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical reports. 2016. Sun Xue, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin Dosing Algorithms and the Need for Human Intervention. The American journal of medicine. 2016. Kasner Scott E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Thrombosis and haemostasis. 2016. Shahabi Payman, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The association between Non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. British journal of clinical pharmacology. 2016. He Ying, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016. Shendre Aditi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016. Hocum Brian Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. Anatolian journal of cardiology. 2016. Dilge Taşkın Birce, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians. Clinical and translational science. 2016. Hamadeh I S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The outlier in all of Us: Why implementing pharmacogenomics could matter for everyone. Clinical pharmacology and therapeutics. 2016. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: A case-control study. Current clinical pharmacology. 2016. Thatte Urmila. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. Pharmacogenomics. 2016. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. Cardiovascular therapeutics. 2015. An Sook Hee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Tracy Timothy S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome medicine. 2016. Bourgeois Stephane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomically actionable medications in a safety net health care system. SAGE open medicine. 2016. Carpenter Janet S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Systematic reviews. 2016. Takeuchi Masanobu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2016. Marek Elizabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Integrated Patient and Tumor Genetic Testing for Individualized Cancer Therapy. Clinical pharmacology and therapeutics. 2015. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. International journal of clinical pharmacology and therapeutics. 2015. Mandic Dario, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Thrombosis research. 2015. Zhang Jinhua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling. Pharmacogenetics and genomics. 2015. Lewis Benjamin C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis. Meta gene. 2015. Tian Lihong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antidotes to coumarins, isoniazid, methotrexate and thyroxine; toxins that work via metabolic processes. British journal of clinical pharmacology. 2015. Bateman D Nicholas, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. European journal of clinical pharmacology. 2015. Chung Jee-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. Journal of thrombosis and haemostasis : JTH. 2015. Abohelaika S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics. 2015. Parra Esteban J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Race influences warfarin dose changes associated with genetic factors. Blood. 2015. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular pharmacogenomics: current status and future directions. Journal of human genetics. 2015. Roden Dan M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation. Pharmacogenetics and genomics. 2015. Syn Nicholas L X, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics. 2015. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2015. Sermsathanasawadi Nuttawut, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clinic proceedings. 2015. Kaufman Amy L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of medical research. 2015. Šupe Svjetlana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59. Drug metabolism and disposition: the biological fate of chemicals. 2015. Dai Da-Peng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenetics and genomics. 2015. Fohner Alison E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials. Journal of cardiovascular pharmacology. 2015. Wang Zhi-Quan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and drug safety. 2015. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thrombosis research. 2015. Li Xiaoqi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiology and drug safety. 2015. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015. Nagai Rui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. European journal of clinical pharmacology. 2015. Chang Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: A systematic review and meta-analysis. Thrombosis research. 2015. Sun Yifan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2015. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Molecular diagnosis & therapy. 2014. de Oliveira Almeida Vanessa Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenetics and genomics. 2014. Drozda Katarzyna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics. 2015. Li Xi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of single nucleotide polymorphisms in c-Myc on stable warfarin doses in patients with cardiac valve replacements. Pharmacogenomics. 2015. Lee Kyung E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014. Kawai Vivian K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. Pharmacogenomics. 2015. Karaca Sefayet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity. Pharmacogenomics. 2015. Chan Sze Ling, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015. You Joyce H S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients. Pharmacogenomics. 2015. Peng Qi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PloS one. 2015. Pengo Vittorio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database. PloS one. 2015. Liu Rong, et al. PubMed
No Dosing Guideline available